TP53 in bone and soft tissue sarcomas

Elizabeth Thoenen [a], Amanda Curl [b], Tomoo Iwakuma [a,b,c,*]

[a] Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66010, USA
[b] Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66010, USA
[c] Translational Laboratory Oncology Research, Children's Mercy Research Institute, Kansas City, MO 64108, USA

ARTICLE INFO

ABSTRACT

Genomic and functional study of existing and emerging sarcoma targets, such as fusion proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic drivers, is broadening our understanding of sarcomagenesis. Among these mechanisms, the tumor suppressor p53 (TP53) plays significant roles in the suppression of bone and soft tissue sarcoma progression. Although mutations in *TP53* were thought to be relatively low in sarcomas, modern techniques including whole-genome sequencing have recently illuminated unappreciated alterations in *TP53* in osteosarcoma. In addition, oncogenic gain-of-function activities of missense mutant p53 (mutp53) have been reported in sarcomas. Moreover, new targeting strategies for TP53 have been discovered: restoration of wild-type p53 (wtp53) activity through inhibition of TP53 negative regulators, reactivation of the wtp53 activity from mutp53, depletion of mutp53, and targeting of vulnerabilities in cells with TP53 deletions or mutations. These discoveries enable development of novel therapeutic strategies for therapy-resistant sarcomas. We have outlined nine bone and soft tissue sarcomas for which TP53 plays a crucial tumor suppressive role. These include osteosarcoma, Ewing sarcoma, chondrosarcoma, rhabdomyosarcoma (RMS), leiomyosarcoma (LMS), synovial sarcoma, liposarcoma (LPS), angiosarcoma, and undifferentiated pleomorphic sarcoma (UPS).

© 2019 Elsevier Inc. All rights reserved.

Contents

1. Introduction

Bone and soft tissue sarcomas are tumors of mesenchymal origin. Sarcomas are exceptionally rare tumors, comprising less than 1% of all human cancers. Most sarcomas arise from abnormal differentiation processes of mesenchymal stem cells (MSCs) and their derived cell lineages (Eid & Garcia, 2015; Lye, Nordin, Vidyadaran, & Thilakavathy, 2016). Sarcomas commonly occur in children and young adults (Ognjanovic, Olivier, Bergemann, & Hainaut, 2012). Sarcoma prognosis remains poor, especially in cases of distant metastasis (Meyer & Seetharam, 2019). Although advanced chemotherapy and surgery have improved patients' prognosis, treatment options for most sarcomas have remained stagnant for the past 30-40 years (Meyer & Seetharam, 2019; Scheidt et al., 2019). Therefore, understanding the molecular mechanisms driving sarcoma malignancy would significantly accelerate development of novel therapeutic strategies.

Advances in molecular biology have enabled precise and detailed discovery in the genome and expression profiles of tumor tissues, as compared with those of non-tumor tissues. Several unappreciated mutations and chromosomal abnormalities are found in osteosarcoma, including genes associated with IGF signaling, alterations in the PI3K/ mTOR pathway, and somatic structural variations in TP53 (Behjati et al., 2017, X. Chen, et al., 2014, Perry et al., 2014, Sayles et al., 2019). Genome sequencing of Ewing sarcoma reveals mutations related to DNA repair machineries (Brohl et al., 2017). Indeed, *Anderson et al.* (Anderson et al., *2018*) *show that* complex chromosome rearrangements at the early stage of Ewing sarcoma development may contribute to EWS-ETS gene fusions and other DNA rearrangements. Additionally, multi-platform molecular landscape analysis of 206 adult soft tissue sarcomas, including leiomyosarcoma (LMS), de-differentiated liposarcoma (LPS), undifferentiated pleomorphic sarcoma (UPS), and synovial sarcoma, has recently revealed previously unappreciated sarcoma-type-specific changes in copy number variation, methylation pattern, RNA expression profile, and protein expression, which could have an impact on sarcoma diagnosis and therapy (Cancer Genome Atlas Research Network. Electronic address & Cancer Genome Atlas Research, 2017). These findings have further confirmed the significance of mutations and genetic abnormalities in the *TP53* gene on bone and soft tissue sarcoma progression. Mutations in *TP53* are detected in about half of all tumors, remaining the most frequently mutated gene in human cancers (Hung & Anderson, 1997; Taubert, Meye, & Wurl, 1998; Zhou, Hao, & Lu, 2018). Previously, mutations in *TP53* were thought to occur at a relatively low frequency in sarcomas (Toguchida et al., 1992). This is mainly because mutations in *TP53* were identified by sequencing only exonic regions in the DNA binding domain or by performing immunohistochemistry (IHC) to detect positive staining in p53-mutated tumors due to the long half-life of the mutant protein. However, recent whole-genome sequencing analyses have revealed more frequent alterations in TP53, including structural alterations in *TP53* intron 1. Thus, the significance of TP53 in sarcoma could have been underestimated, which drives us to revisit the roles of TP53 in sarcomagenesis. Since a variety of alterations to TP53 and TP53 upstream regulators are detected in sarcomas, we will also discuss several distinct TP53 targeting strategies in this review article (Table 1).

TP53 is a transcription factor that is stabilized following genotoxic stress and induces transcription of genes associated with cell cycle arrest, apoptosis, and metabolism, thereby functioning as a tumor suppressor (Lane & Levine, 2010, Ranjan & Iwakuma, 2016). Typically, tumor suppressors have loss-of-function (LOF) mutations or deletions in cancers; however, the majority of TP53 mutations are missense mutations in the DNA binding domain, such that mutant TP53 (mutp53) not only loses the tumor suppressive function but also gains oncogenic functions (GOF: gain of function) independent of wild-type TP53 (wtp53) (Parrales & Iwakuma, 2015). The most frequently mutated codons are R175, R248, and R273. There are roughly two types of TP53 mutations. The first is a DNA contact type in which mutations occur at

Table 1
Strategy targeting TP53.

TP53 status	Targeting Strategy
Wild-type TP53 (reduced activity)	Restoration of wild-type TP53 activity: MDM2 antagonists (Nutlin-3a, RG7112, SAR405838, APG-115, AMG 232, MK-8242), MDM4 inhibitors (CTX1, K-181, SJ-172550), MDM2/4 dual inhibitors (DIMP53-1, pDI analogs), RITA
TP53-null	Target vulnerabilities in cells lacking wild-type TP53 activity: Inhibitors for wee1 kinase, Chk1, Chk2, ATM, MK2, and polo-like kinase 1
Mutant TP53	Target vulnerabilities in cells lacking wild-type TP53 activity: Inhibitors for wee1 kinase, Chk1, Chk2, ATM, MK2, and polo-like kinase 1; Reactivation of wild-type TP53 activity from mutant TP53: PRIMA-1, APR-246, CP-31398, STIMA-1, Stictic acid; Mutant TP53 depletion: Statins, HSP90 inhibitors

amino acids that directly interact with DNA (e.g., K120, R248, R273, R280). The second is a conformational or misfolded type, in which mutations do not occur in DNA-contacting amino acids but instead alter the three-dimensional structure of TP53, thereby losing the DNA binding activity (Adhikari & Iwakuma, 2009, D. Lane & Levine, 2010). Increasing evidence suggests that not all TP53 mutants have identical GOF activity. However, overall, the majority of TP53 mutants lose tumor suppressive function, at least partially, and some mutants show distinct oncogenic activities to promote malignant progression (M. P. Kim & Lozano, 2018, Mantovani, Collavin, & Del Sal, 2019, Parrales & Iwakuma, 2015). These mutants' oncogenic properties are seen throughout a variety of cancers including bone and soft tissue sarcomas.

Mutp53's oncogenic properties are also demonstrated in Li-Fraumeni syndrome (LFS), an autosomal dominant familial cancer-prone syndrome. The link between germline mutations of *TP53* and LFS was confirmed by molecular testing in 1990 (Malkin et al., 1990). Over 70% of patients with LFS inherently harbor a mutation in the *TP53* gene in their germlines and frequently develop various types of cancer at early ages, including osteosarcoma, rhabdomyosarcoma (RMS), brain tumors, breast cancer, leukemias, and adrenocortical carcinoma (Correa, 2016; Malkin et al., 1990). Osteosarcoma is the most common sarcoma in patients with LFS, though rates are only slightly higher for osteosarcoma than brain tumors and RMS (Correa, 2016; Guha & Malkin, 2017). Even a low-penetrance *TP53* R337H mutation, found in a clustered population in southeast Brazil, is associated with an increased frequency of adrenocortical tumors, choroid plexus carcinoma, and osteosarcoma (Seidinger et al., 2011). Additionally, Mirabello et al. (Mirabello et al., 2015) report that young-onset osteosarcoma has a higher frequency of LFS-associated *TP53* mutations. Moreover, they show that the presence of a rare *TP53* variant leading to an exonic splice site change, rs1800372 (p.R213R), is associated with metastasis at diagnosis of osteosarcoma (Mirabello, Yeager, et al., 2015).

In this review article, we revisit the significance of TP53 in bone and soft tissue sarcoma with updated literatures by focusing on osteosarcoma, Ewing sarcoma, chondrosarcoma, RMS, LMS, synovial sarcoma, LPS, angiosarcoma, and UPS. For each sarcoma we explore the roles of TP53 in tumor development, malignancy, and the prognosis of these sarcomas, as well as potential and optimal therapeutic strategies targeting TP53 for each sarcoma (Table 2).

2. Osteosarcoma

Osteosarcoma is the most common primary cancer of the bone and arises during the process of osteoblastic differentiation from MSCs (Mortus, Zhang, & Hughes, 2014; Tang, Song, Luo, Haydon, & He, 2008). Osteosarcoma is commonly detected near the epiphyseal plate of long bones, most commonly in children. A combination of surgery and chemotherapy, including high-dose methotrexate, cisplatin, and doxorubicin, is the main therapeutic strategy for osteosarcoma.

Table 2
TP53 mutation rate in sarcomas and suitable targeting strategies.

Sarcoma	Overall TP53 mutation rate	Notable TP53/MDM2 alterations	Suitable TP53 targeting strategies
Osteosarcoma	~80%	1) *TP53* intron 1 rearrangements, 2) *MDM2/MDM4* gene amplification	1) MDM2/MDM4 antagonists to restore wild-type TP53 activity, 2) Targeting vulnerability imposed by TP53 deletion/mutations
Ewing sarcoma	~10%	1) Inhibition of wild type TP53 by EWS-FLI1 fusion protein	1) Restoring wild-type TP53 activity
Chondrosarcoma	~20%	1) *MDM2* gene amplification, 2) Alterations in the TP53 pathway in >50% of cases	1) Restoring wild-type TP53 activity by MDM2 antagonists, 2) Targeting vulnerabilities imposed byTP53 deletion/mutations
Rhabdomyosarcoma	< 15%	1) Reduced wild-type TP53 activity and expression by PAX-FHKR and PAX proteins, 2) TP53 deletions/mutations in E2 subtype of ERMS	1) Restoring wild-type TP53 activity, 2) Targeting vulnerabilities imposed by TP53 deletion/mutations, reactivating wild-type TP53 activity from mutant TP53, or depleting mutant TP53 (ERMS)
Leiomyosarcoma	~50%	1) TP53 missense mutations	1) Targeting vulnerabilities imposed by TP53 mutations, reactivating wild-type TP53 activity from mutant TP53, or depleting mutant TP53
Synovial sarcoma	~5%	1) Inhibition of wild-type TP53 by SS18-SSX and *MDM2/MDM4* gene amplification	1) Restoring wild-type TP53 activity by MDM2/MDM4 antagonists
Liposarcoma	10-20%	1) *MDM2* gene amplification, 2) TP53 missense mutations in pleomorphic LPS	1) Restoring wild-type TP53 activity by MDM2 antagonists, 2) Targeting vulnerabilities imposed by TP53 deletion/mutations, reactivating wild-type TP53 activity from mutant TP53, or depleting mutant TP53 (Pleomorphic LPS)
Angiosarcoma	< 50%	1) TP53 missense mutations, 2) MDM2 upregulation	1) Targeting vulnerabilities imposed by TP53 deletion/mutations, reactivating wild-type TP53 activity from mutant TP53, or depleting mutant TP53, 2) Restoring wild-type TP53 activity by MDM2 antagonists
Undifferentiated pleomorphic sarcoma	~30%	1) Retaining one wild-type TP53 allele in > 85% or p14ARF deletion/silencing, 2) TP53 missense mutations	1) Restoring wild-type TP53 activity by MDM2 antagonists, 2) Targeting vulnerabilities imposed by TP53 deletion/mutations, reactivating wild-type TP53 activity from mutant TP53, or depleting mutant TP53

Although this treatment has improved 5-year survival rate of patients to 70% in the past three decades, some patients develop resistance to chemotherapy, and the long-term survival of patients with relapse remains below 20% (Harrison, Geller, Gill, Lewis, & Gorlick, 2018; Zhang et al., 2018). To overcome this poor prognosis, it is crucial to learn about the genetics and molecular pathogenesis of this disease.

Osteosarcomas frequently show complex karyotypes and genomic instability including gene amplifications (*MYC, CCNE, Rad21, VEGFQ, AURKB, CDK4*), deletions (*TP53, RB1, PTEN*), somatic nucleotide variants (SNVs) or short indels (*TP53, ATRX, RBs, PRKDC*), and structural variants (SVs: *TP53, LRP1B, RB1, FHIT*) (Martin, Squire, & Zielenska, 2012; Sayles et al., 2019). While many other sarcomas are often characterized by chromosomal translocations (including Ewing sarcoma, RMS, synovial sarcoma, and LPS), until now no such representative translocation has been identified in osteosarcoma (Martin et al., 2012). Mutation of *TP53* is well-correlated with genomic and chromosomal instability in human high-grade osteosarcoma (Al-Romaih et al., 2003; Zuffa et al., 2008). One early immunohistochemistry (IHC) study shows that 27 out of 46 (58.7%) osteosarcoma specimens exhibit TP53 overexpression, a common indicator of TP53 missense mutations (Guo, Wang, & Feng, 1996), while other studies show fewer TP53 mutations in osteosarcoma (Mendoza, Konishi, Dernell, Withrow, & Miller, 1998; Miller et al., 1996; Mirabello et al., 2015). Intriguingly, Masuda, Miller, Koeffler, Battifora, & Cline (1987) first reported intron 1 rearrangements in the *TP53* gene in 3 out of 6 human osteosarcoma samples in 1987. Indeed, a recent whole-genome sequencing of 34 osteosarcoma samples has discovered similar mutations in the *TP53* gene. Nine (26%) have *TP53* point mutations, and 19 (55%) have structural variations in the *TP53* gene, the majority of which are translocations with breakpoints in the first intron (Chen, et al., 2014). This finding is supported by the report by Ribi et al. (Ribi et al., 2015), where 16% of sporadic osteosarcomas show intron 1 rearrangements, while no other tumors have such *TP53* rearrangements. The intron 1 rearrangements are also detected in a four-generation LFS family (Ribi et al., 2015). The most recent study by Sayles et al. (2019) demonstrates that *TP53* alterations including structural variation (SV) and somatic nucleotide variants (SNVs) are detected in 74% of human osteosarcoma. Since rearrangements in intron 1 cannot be detected by exon sequencing and IHC, alterations in *TP53* have likely been underestimated. Biologically, loss of TP53 activity is shown to promote osteogenic differentiation of bone marrow stromal cells, as well as osteosarcoma development from MSCs (He et al.,

2015; Velletri et al., 2016). Thus, TP53 has strong impact on preventing the malignant transformation of MSCs.

Genetic deletion or mutations of *TP53* in mice with the C57BL/6 background often results in osteosarcoma development (Lang et al., 2004). Also, mice expressing a gain-of-function (GOF) TP53R172H (R172H is equivalent to human R175H) spontaneously develop metastatic tumors, including osteosarcoma, at a high frequency (~30% in the C57BL/6 background) (Lang et al., 2004; Olive et al., 2004). This metastatic GOF activity by mutp53 can be mediated by upregulation of the ONZIN-CXCL5-MAPK axis or by binding of mutp53 with TP63, TP73, and ETS2 (Do et al., 2012; Lang et al., 2004; Pourebrahim et al., 2017; Xiong et al., 2014; Zhang et al., 2018). Moreover, combined deletion of *TP53* and *RB1* in mouse osteoblasts results in development of metastatic osteosarcoma at a high frequency (Walkley et al., 2008). Thus, deletions and mutations in *TP53* significantly contribute to osteosarcoma progression in mouse models, supporting findings in humans.

TP53 has been implicated in chemotherapy sensitivity, mainly through induction of apoptosis and senescence as well as inhibition of autophagy (Fan & Bertino, 1999, Hu et al., 2017, Wang & Sun, 2010). Previous studies have shown that mutations in *TP53* are associated with chemoresistance or poor event-free survival in human osteosarcoma (Goto et al., 1998; Tsuchiya et al., 2000). Loss of heterozygosity (LOH) of *TP53* in osteosarcomas is associated with chemoresistance (Goto et al., 1998). The work by Asada, Tsuchiya, & Tomita (1999) supports this, showing that deletion of *TP53* is found in an osteosarcoma cell line with acquired resistance to cisplatin. However, multiple meta-analyses suggest that while TP53 mutations could only serve as an effective prognostic marker for 2- or 3-year overall survival of patients with osteosarcoma, TP53 status does not appear to be correlated with development of metastases or chemotherapy response in patients with osteosarcoma (Chen, Guo, Zhang, & Guo, 2016, Fu et al., 2013, Gokgoz et al., 2001, Pakos, Kyzas, & Ioannidis, 2004, Wunder et al., 2005, Yao et al., 2014). However, these clinical studies do not examine the structural alterations in *TP53* introns. Considering frequent observations of the *TP53* intron 1 rearrangement, it may be important to re-evaluate the clinical significance of TP53 alterations in malignancy, response to chemotherapy, and metastasis of human osteosarcoma and other types of cancer.

Alterations to regulators of TP53 can also contribute to development of osteosarcoma (Morrow & Khanna, 2015). One crucial regulator of TP53 stability and degradation is the protein MDM2 (murine double minute 2). MDM2, which acts as the major E3 ubiquitin ligase for

TP53, is overexpressed in ~30% of human cancers. *MDM2* copy number is amplified more than 3-fold in 14.7% of high grade osteosarcoma (Overholtzer et al., 2003). Ito et al. (Ito et al., 2011) show that 35% of osteosarcoma cases have over 3-fold *MDM2* amplification. However, mutations in *TP53*, but not copy number of *MDM2*, are correlated with overall genomic instability in high-grade human osteosarcoma (Overholtzer et al., 2003). Although a multivariate analysis shows that the *MDM2* polymorphism T309G which increases MDM2 expression levels via an extra SP1 binding site in the *MDM2* promoter is associated with an increased risk of developing high-grade osteosarcomas in female patients (Toffoli et al., 2009), there is no conclusive literature showing correlation of MDM2 overexpression with survival and prognosis of human osteosarcoma.

Another major inhibitor of TP53 is MDM4 (Haupt, Hernandez, Vijayakumaran, Keam, & Haupt, 2019). Although it is a homolog of MDM2, MDM4 does not have ubiquitin ligase activity like MDM2. However, MDM4 still binds with TP53 and inhibits TP53 activity. Also, MDM4 hetero-dimerizes with MDM2 through the C-terminal RING finger domain to induce TP53 degradation as a cofactor of MDM2 (Haupt et al., 2019). Similar to MDM2, 35% of osteosarcoma cases show *MDM4* amplification over 3-fold (Duhamel et al., 2012; Ito et al., 2011). In addition, multiple studies have highlighted the expression of *MDM4* splice variants in different tumor types (Bardot & Toledo, 2017). One *MDM4* splice variant, *MDM4-S*, which skips exon 6 and prematurely terminates in exon 7, encodes a truncated MDM4 protein carrying only the N-terminal TP53-binding domain along with 13 novel amino acids (Bardot & Toledo, 2017; Pant et al., 2017). Overexpression of *MDM4-S* has been linked to poor prognosis in osteosarcoma, soft tissue sarcoma, and other cancers (Dewaele et al., 2016; Lenos et al., 2012; Lenos & Jochemsen, 2011). *Thus, MDM4-S* overexpression can serve as an effective biomarker for TP53 pathway attenuation in cancers (Lenos et al., 2012).

2.1. Pagetic osteosarcoma and TP53

Paget's disease of bone (PDB), which occurs in approximately 3% of adults over 50 years old, is a metabolic bone disease characterized by increased bone resorption and subsequent excessive disorganized bone formation (Ouslander & Beck, 1982). PDB occurs rarely in Asian and African regions, while individuals in Europe, North America, and Australia show a high prevalence rate of PDB (Gennari, Rendina, Falchetti, & Merlotti, 2019; Gruener & Camacho, 2014). One of the genes implicated in PDB is Sqstm1/p62, which plays roles in NF-κB activation as a scaffolding/adaptor protein and selective macroautophagy as an autophagosome cargo protein (Duran et al., 2008, Fan, Yin, Zhang, & Hu, 2018, McManus & Roux, 2012). Patients with PDB have a high incidence of osteosarcoma, called Pagetic osteosarcoma. The prevalence of Pagetic osteosarcoma is estimated to be about 1%, which is several hundred- to thousand-fold higher than the prevalence of osteosarcoma in the general population depending on the age (Greditzer 3rd, McLeod, Unni, & Beabout, 1983; Hansen, Nellissery, & Bhatia, 1999; Mirabello, Troisi, & Savage, 2009). Pagetic osteosarcoma accounts for 50% of osteosarcoma cases in patients over 60 years of age (Gennari et al., 2019; Yochum, 1984). Although *MYC* gene amplification and *TP53* mutations are detected in Pagetic osteosarcomas and loss of TP53 activity is reported to reduce Sqstm1/p62 levels, the direct role of TP53 in Pagetic osteosarcoma development remains unclear (Goiran et al., 2018; Reddy, 2004; Ueda, Healey, Huvos, & Ladanyi, 1997).

2.2. TP53-targeted therapy in osteosarcoma

Because TP53 alterations have been underestimated in osteosarcoma, most early studies in osteosarcoma focus on restoring wtp53 activity by inhibiting a TP53 negative regulator, MDM2 (Table 1) (Hientz, Mohr, Bhakta-Guha, & Efferth, 2017). The first report for an MDM2 inhibitor is Nutlin-3a (Vassilev et al., 2004). Nutlin-3a binds MDM2 in the TP53-binding pocket and activates TP53 without causing DNA damage in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition in osteosarcoma xenograft mouse models (Tovar et al., 2006, Vassilev et al., 2004, Wang, Fang, Zhao, Xiang, & Wang, 2012). Nutlin-3a shows synergy with other chemotherapy drugs and CDK inhibitors, and oridonin, a diterpenoid extracted from medicinal herbs (Cheok, Dey, & Lane, 2007, Wang, Zhang, Bao, & Liu, 2017). Unfortunately, clinical trials for Nutlin-3a in various tumor types have yet to show much success due to significant side-effects including bone marrow suppression (Ray-Coquard et al., 2012). Several other compounds that inhibit MDM2-TP53 binding have been identified, including RG7112 (Tovar, et al., 2013), SAR405838 (Wang et al., 2014), APG-115 (Yi et al., 2018), AMG 232 (Sun et al., 2014), and MK-8242 (Wagner et al., 2017). Some of these MDM2 inhibitors are currently in clinical trials (Lane, Brown, Verma, & Cheok, 2011, Morrow & Khanna, 2015, Tovar, et al., 2013, Wagner et al., 2017, Wang et al., 2014). Besides MDM2 inhibitors, investigators have discovered MDM4 inhibitors (e.g., CTX1, K-181, SJ-172550), as well as MDM2/MDM4 dual inhibitors (e.g., DIMP53-1, pDI analogs) (Bista et al., 2012; Karan et al., 2016; Philippe et al., 2016; Soares et al., 2017; Uesato et al., 2016). The effects of these inhibitors on osteosarcoma need to be tested in the future.

When tumors carry missense mutp53, restoration of wtp53 activity from mutp53 can be an efficient strategy for anti-cancer therapy (Table 1) (Parrales & Iwakuma, 2015). PRIMA-1 is the first small molecule that is shown to restore sequence-specific DNA binding and transcriptional activities of TP53 with tumor suppressive effects in mutp53-expressing cells (Bykov et al., 2005). Since then, many compounds have been identified, and details of these compounds are summarized elsewhere (Binayke, Mishra, Suman, Das, & Chander, 2019, Bykov, Eriksson, Bianchi, & Wiman, 2018, Parrales & Iwakuma, 2015). Of these, APR-246, a PRIMA-1 analog, shows synergy in inhibiting tumor cell growth with camptothecin, a quinoline alkaloid, in the Saos2 osteosarcoma cell line exogenously expressing TP53 R273H (Saos2-TP53R273H) (Bykov et al., 2005). STIMA-1, a small molecule compound with structural similarities to CP-31398 that stabilizes the active conformation of TP53 (Wischhusen, Naumann, Ohgaki, Rastinejad, & Weller, 2003), is also shown to stimulate DNA binding of mutp53, induce expression of TP53 target genes, and trigger apoptosis in H1299-TP53R175H lung adenocarcinoma and Saos2-TP53R273H osteosarcoma cells (Zache et al., 2008). Additionally, stictic acid, which was identified though computational methods for a transiently open binding pocket in the TP53 core domain, is shown to upregulate p21 and PUMA in Saos2 cells expressing TP53 R175H and G245S (Wassman et al., 2013).

Other than these compounds to increase wtp53 activity, drugs that can deplete mutp53 can also be used to inhibit tumor growth of mutp53-expressing osteosarcoma. This is based on the observations that cancer cells are addicted to oncogenes, including mutp53, and that depletion of mutp53 may lead to reactivation of proteins or pathways suppressed by mutp53 (Iyer et al., 2016; Parrales & Iwakuma, 2015). HSP90 inhibitors and cholesterol-lowering drugs (statins) are agents that have been shown to induce degradation of mutp53 mediated by MDM2 and/or CHIP ubiquitin ligases and inhibit tumor progression including osteosarcoma (Alexandrova et al., 2015; Parrales et al., 2016).

Another way to target TP53 mutations is to treat cells with a compound that inhibits proteins or pathways unique and essential for survival and proliferation (vulnerabilities) in *TP53*-null or mutated cells with minimal impact on wtp53-expressing cells (Table 1) (Lu et al., 2016; Tongyang et al., 2015). Such a compound may inhibit function of proteins that show a synthetically lethal interaction with TP53 mutations, including CHK1, ATM/CHK2, Plk1, Wee1, and MK2 (Chung et al., 2018, Gurpinar & Vousden, 2015, Harada et al., 2011, Jiang et al., 2009, Morandell et al., 2013, Origanti, Cai, Munir, White, & Piwnica-Worms, 2013, Tongyang et al., 2015, Wang & Simon, 2013, Weidle, Maisel, & Eick, 2011). Since ~80% of osteosarcoma cases have TP53 alterations,

targeting vulnerable pathways and proteins in cells lacking wtp53 activity would be a reasonable treatment strategy. Intriguingly, through a 54 FDA-approved agent screen, Yu et al. (2015) identify HDAC (histone deacetylase) inhibitors as agents having anti-growth activity and synergistic effects with proteasome inhibitors in five TP53-inactive pediatric osteosarcoma cell lines; however, the underlying mechanism remains unclear.

3. Ewing sarcoma

Ewing sarcoma accounts for approximately 1% of childhood cancers and is the second most common bone cancer in children, although it can also arise in soft tissues (Grunewald et al., 2018). The femur is the most frequently affected bone. The origin of Ewing sarcoma remains controversial as both MSCs and neural crest stem cells (NCSCs) have been implicated as the cell of origin (Lin, Wang, & Lozano, 2011; Todorova, 2014). Microscopically, the tumor consists of small round cells with regular round nuclei and a narrow rim of clear or faintly eosinophilic cytoplasm (Burchill, 2003).

The current chemotherapy protocols for Ewing sarcoma include combinations of doxorubicin, cyclophosphamide, vincristine, actinomycin-D, ifosfamide, and etoposide (Ozaki, 2015). These treatments have improved the overall 5-year survival of localized Ewing sarcoma to 70%. However, overall survival of metastatic Ewing sarcoma remains stagnant at ~30% (Balamuth & Womer, 2010; Kridis et al., 2017).

This malignancy is characterized by translocation between a gene of the RNA-binding TET family (e.g., EWSR1, FUS) and a gene of the ETS-transcription family (e.g., FLI1, ERG, ETV1, ETV4, and FEV). In the majority of cases (~85%), the EWS-FLI1 fusion resulting from a t(11;22) translocation is detected (Renzi, Anderson, Light, & Gupta, 2019). However, it remains unclear why this fusion occurs and how exactly the fusion protein contributes to Ewing sarcoma development. A recent study by Anderson et al. (2018) using whole-genome sequence analyses of 124 Ewing sarcomas indicates that chromoplexy, a sudden burst of loop-like genomic rearrangements involving multiple chromosomes and genes, rather than reciprocal translocation, is the potential cause of the EWSR1–ETS fusion in 42% of cases. The loop-like genomic rearrangements and fusions are also detected in other sarcomas including chondromyxoid fibroma and synovial sarcoma (Anderson et al., 2018).

Molecular and genetic profiles of Ewing sarcoma have been assessed in a genome-wide association study of 733 Ewing sarcoma cases and 1,346 unaffected individuals of European ancestry by Crompton et al. (2014). They reveal new susceptibility loci at 6p25.1, 20p11.22, and 20p11.23, in addition to previously reported loci at 1p36.22, 10q21.3, and 15q15.1. They identify candidate genes at 6p25.1 (RREB1) and 20p11.23 (KIZ) (Crompton et al., 2014). Brohl et al. (2014) also show that Ewing sarcoma has frequent mutations in the cohesin complex subunit STAG2 (21.5%), homozygous deletion of CDKN2A (13.8%) and mutations of TP53 (6.2%), as well as an increased prevalence of the BRCA2 K3326X polymorphism (7.3%). Other genome sequencing studies also identify mutations in cancer-related genes including KDR, STK11, MLH1, KRAS, and PTPN11, as well as in DNA double-strand break repair, in Ewing sarcoma tissues (Brohl et al., 2017; Zhang et al., 2016).

With regard to TP53 mutations, multiple articles have found that genetic alterations in the TP53 gene are detected only in ~10% of Ewing sarcomas (Komuro et al., 1993; Lerman, et al., 2015; Neilsen, Pishas, Callen, & Thomas, 2011; Radig et al., 1998). The two most frequently detected TP53 mutations in Ewing sarcoma are the C176F and R273X (Sand, Szuhai, & Hogendoorn, 2015). Although mutation frequency of TP53 is low in Ewing sarcoma, TP53 still plays a crucial role in inhibiting Ewing sarcoma progression. Li et al. (2010) report that EWS-FLI1 binds to and inhibits TP53's transcriptional activity, which may explain why TP53 mutations are detected only in ~10% of Ewing sarcoma. To support this finding, silencing of EWS-FLI1 reactivates NOTCH signaling and subsequently activates TP53 to induce cell cycle arrest in Ewing sarcoma

cells (Ban et al., 2008). Additionally, EWS-FLI1 significantly inhibits p300-mediated acetylation of TP53 at Lys-382 (Y. Li et al., 2012). These results strongly suggest the inhibitory role of EWS-FLI1 in TP53 activity as well as the vital tumor inhibitory role of TP53 in Ewing sarcoma progression. However, a study by Lessnick, Dacwag, & Golub (2002) shows that EWS-FLI1 induces a TP53-dependent growth arrest in primary human fibroblasts, which is rescued by wtp53 inhibition. The observed discrepancy may be due to difference in the experimental settings including cancer cells vs non-transformed cells.

Several clinical studies also support the important role of TP53 in inhibiting Ewing sarcoma progression. An IHC study by de Alava et al. (2000) shows that positive TP53 staining in Ewing's sarcoma is a poor prognostic factor. This finding is supported by studies by Huang et al. (2005)) and Abudu et al. (1999), demonstrating significant correlation of TP53 mutations with poor overall survival and response to chemotherapy. On the other hand, a study by Lerman, et al. (2015) fails to observe an association between TP53 mutations and event-free survival of patients. The discrepancy among these studies may be caused by the methodology used to determine TP53 mutations. Whole-genome sequencing, rather than IHC and exome sequencing, would be necessary to clarify the significance of TP53 mutations in Ewing sarcoma.

Similar to osteosarcoma, MDM2 overexpression is not high (~10%) (Kovar et al., 1993). Ladanyi et al. (1995) report that only three out of 30 Ewing sarcoma specimens have MDM2 gene amplification, all of which have metastasis at diagnosis, while only one out of 15 specimens without MDM2 amplification has metastasis, suggesting correlation between MDM2 amplification and metastasis. Thus, the TP53 pathway may play a crucial role in the suppression of Ewing sarcoma progression.

Given the infrequent rate of mutations of TP53 in Ewing sarcoma, restoring TP53 activity by inhibiting upstream inhibitors of TP53 is a rational therapeutic strategy (Neilsen et al., 2011; Stolte et al., 2018). Through a genome-scale CRISPR-Cas9 screening, Stolte et al. (2018) identify MDM2, MDM4, USP7, and PPM1D as druggable targets for Ewing sarcoma. They also demonstrate that ATSP-7041, a stapled peptide inhibitor of MDM2 and MDM4, shows anti-tumor efficacy in vitro and in mouse models. Additionally, P5091, a USP7 inhibitor, and GSK2830371, a Wip1/PPM1D inhibitor, decrease viability of Ewing sarcoma cells, in a TP53-dependent manner (Stolte et al., 2018). Pishas et al. (2011) show that Nutlin-3a induces cell death, mainly apoptosis, in Ewing sarcoma cells expressing wtp53, and Nutlin-3a's effect is synergistic with the chemotherapeutic agents: vincristine, actinomycin D, doxorubicin, and etoposide. Similarly, Sonnemann et al. (2011) observe that nutlin-3a induces apoptosis and senescence with increased TP53 level and mRNA expression of TP53 downstream target genes in wtp53-expressing Ewing sarcoma cells (Sonnemann et al., 2011). Also, YK-4-279, a small molecule inhibitor of EWSR1–ETS's transcriptional activity through inhibition of its interaction with RNA helicase A, is shown to reduce Ewing sarcoma development regardless of TP53 status. The effects of YK-4-279 are additive with Nutlin-3a, in vitro and in a xenograft zebrafish model of human Ewing sarcoma cell lines (van der Ent et al., 2014). Another way to restore wtp53 activity in Ewing sarcoma is to inhibit CD99. CD99 is expressed in most cases of Ewing sarcoma and is required to maintain malignancy (Pasello, Manara, & Scotlandi, 2018; Ventura et al., 2016). Guerzoni et al. (2015) find that dAbd C7, a novel human monospecific bivalent single-chain fragment variable diabody against CD99, induces cell death in Ewing sarcoma cells, through MDM2 degradation and TP53 reactivation; the anti-CD99 dAbd C7 shows additive effects with doxorubicin to suppress Ewing sarcoma malignancy.

When Ewing sarcoma expresses mutp53, APR-246 can be used to induce apoptosis by reactivating wtp53 activity in tumors. APR-246 is currently in early-phase clinical trials for Ewing sarcomas (Aryee et al., 2013). Intriguingly, curcumin may radiosensitize TP53-mutated Ewing sarcoma cells by upregulating p21 and Bax and downregulating BCL-XL and MCL1, although the mechanism behind reactivation of wtp53 from mutp53 remains unclear (Veeraraghavan, Natarajan, Herman, &

Aravindan, 2010). Another small molecule TP53 reactivator, RITA/ NSC652287, is shown to induce apoptosis and effectively reduce tumor growth of Ewing sarcoma cell lines; however, this effect of RITA is independent of the TP53 status. As an additional mechanism of action of RITA in Ewing sarcoma cells, RITA induces degradation of IGF-1R, a regulator of anchorage-independent growth, in a manner dependent on MDM2 (Di Conza et al., 2012). More studies are required for evaluating efficacy of targeting the TP53 pathway for Ewing sarcoma therapy.

4. Chondrosarcoma

Chondrosarcoma is a heterogeneous group of bone malignancies with cartilage-forming tumor cells, and it is the second most common form of primary malignant bone tumor (Chow, 2018, Kim, Cho, Ayala, & Ro, 2011). Chondrosarcoma generally grows slowly and rarely metastasizes, and the prognosis of surgically resected chondrosarcoma is good with a ~50% 5-year survival rate (Kim et al., 2011). However, chondrosarcoma is generally chemo- and radiotherapy resistant, likely due to a low percentage of dividing cells and poor tumor vascularization. Because surgical resection is the primary treatment for chondrosarcoma, more efficient treatment options for metastatic and recurrent disease are required (Gelderblom et al., 2008).

Genetically, chondrosarcoma can be subtyped to chromosomal translocation-positive and translocation-negative types. Extraskeletal myxoid chondrosarcoma, a slow-growing, low-grade sarcoma with high frequency of metastases and local recurrence, has a t(9;22)(q22; q12) translocation, creating the EWSR1-NR4A3, RBP56-NR4A3, and TCF12-NR4A3 fusion genes, while mesenchymal chondrosarcoma, a rare, fast-growing, high-grade sarcoma, has a HEY1-NCOA2 fusion gene resulting from intrachromosomal rearrangement of 8q21.13 and 8q13.3 or a IRF2BP2-CDX1 fusion gene resulting from t(1;5)(q42;q32) (Chow, 2018, Nazeri, Gouran Savadkoohi, Majidzadeh, & Esmaeili, 2018, Nyquist et al., 2012, Panagopoulos et al., 2002, Sandberg, 2004, Stenman, Andersson, Mandahl, Meis-Kindblom, & Kindblom, 1995, Wang et al., 2012). On the other hand, de-differentiated chondrosarcoma, a high grade, non-chondroid sarcoma associated with low-grade cartilaginous lesions, have structural aberrations in chromosomes 1 and 9, as well as numerical aberrations (trisomy and tetrasomy) in chromosomes 7 and 19, without having distinct chromosomal translocations (Bridge, Bhatia, Anderson, & Neff, 1993; Dijkhuizen et al., 1994; Hameed et al., 2009; Olsson, Paulsson, Bovee, & Nord, 2011; Sakamoto, 2014). Also, clear cell chondrosarcoma, a rare, slow-growing low-grade sarcoma with low metastatic potential, does not have chromosomal translocations.

A whole-genome sequencing analysis by Tarpey et al. (2013) reveals that 37% of chondrosarcoma cases have COL2A1γ gene deletion and rearrangements, while mutations in IDH1/2 are found in 59% of cases, similar to the previous findings by Amary et al. (2011)) and Totoki et al. (2014). Additionally, they detect mutations in TP53 (20%), the RB pathway (33%), and Hedgehog signaling (18%) (Tarpey et al., 2013). Mutations in TP53 and RB1 are the most common changes involved in the later stage of chondrosarcoma (Oshiro et al., 1998; Samuel, Costa, & Lindskog, 2014). Also, deletion and silencing of p16, an upstream regulator of RB1, are implicated in de-differentiated chondrosarcoma (Asp et al., 2000; Sakamoto, 2014). In conventional and de-differentiated chondrosarcoma, alterations in the TP53 gene are observed in 20–50% of cases, while alterations in the RB pathway are detected in 30-96% of cases, depending on the methods of detection (exome sequencing or IHC) (Blasenbreu et al., 1998; Schrage et al., 2009; Tarpey et al., 2013). A higher incidence of TP53 mutation is found in atypical chondrosarcomas, de-differentiated types, and mesenchymal types, while overexpression (indicating missense mutations) or alteration in TP53 is correlated with high histologic grade, presence of metastasis or local recurrence, and reduced overall survival (Dobashi et al., 1993; Oshiro et al., 1998; Simms, Ordonez, Johnston, Ayala, & Czerniak, 1995; Wadayama, Toguchida, Yamaguchi, Sasaki, & Yamamuro, 1993).

Moreover, overexpression of MDM2 by IHC is found in 33% of high-grade chondrosarcoma, which is positively correlated with histological grades (Schrage et al., 2009). Thus, the TP53 pathway is altered in over half of high-grade chondrosarcomas. Furthermore, a mouse model overexpressing Gli2, a protein that plays a role in regulating growth plate chondrocyte differentiation, in combination with TP53 heterozygosity develops chondrosarcoma. This is due to additive effects of overexpression of Gli2 and TP53 deficiency on inhibition of apoptosis mediated through IGFBP3 downregulation in chondrocytes (Ho et al., 2009, Kim et al., 2011).

Chemotherapy is generally not effective in chondrosarcoma with the exception of mesenchymal chondrosarcoma (Dai, Ma, He, & Jha, 2011). As mentioned above, signaling pathways of IGF, Hedgehog, RB, and TP53, as well as these interactions, are implicated in chondrosarcoma progression, and these pathways can be potential therapeutic targets (Bovee, Hogendoorn, Wunder, & Alman, 2010; Jamil, Howie, & Salter, 2010). Intriguingly, van Oosterwijk et al. (2013) identify that the Src pathway is involved in chondrosarcoma chemoresistance. To support their finding, dasatinib, a dual BCR/ABL and Src family tyrosine kinase inhibitor, is shown to be effective in a phase 2 clinical study for multiple sarcomas, including chondrosarcoma, and significantly sensitizes chondrosarcoma cell lines harboring TP53 mutations to doxorubicin, (Schuetze et al., 2017). Appropriate TP53-tageting agents may be chosen to enhance efficacy of current treatment regimens for chondrosarcoma, depending on TP53 status (Polychronidou et al., 2017).

5. Rhabdomyosarcoma (RMS)

Rhabdomyosarcoma (RMS) is a malignant tumor most commonly found in the head & neck, trunk, genitourinary tract, or limbs, and accounts for about half of all childhood soft tissue sarcomas (Egas-Bejar & Huh, 2014). RMS is generally thought to derive from the myogenic progenitors of striated muscle or MSCs, with the specific cell of origin (e.g. satellite cells, myoblasts) determining RMS subtype and therapy (Abraham et al., 2014, Sun et al., 2015). The main varieties of RMS are alveolar RMS (ARMS), embryonal RMS (ERMS) which has two histopathologic variants: spindle cell and botryoid (Esiashvili, Prabhu, Kahn, & Paulino, 2013), and pleomorphic RMS (PRMS) (Ruiz-Mesa, Goldberg, Coronado Munoz, Dumont, & Trent, 2015). The ERMS and ARMS subtypes are most common in children and adolescents, while adults typically develop PRMS (Egas-Bejar & Huh, 2014, Ruiz-Mesa et al., 2015). Remission rates for RMS with modern therapies are now >90% in children without metastasis (Mazzoleni, et al., 2005); however, the 5-year survival rate for metastatic RMS remains less than 30%, and adult RMS also shows poor prognosis (Egas-Bejar & Huh, 2014).

RMS can also be subtyped to chromosome translocation-positive (ARMS) and -negative (ERMS, PRMS) types. The majority of ARMS cases (~85%) express PAX-FKHR fusion proteins resulting from translocation of a PAX family member (i.e. PAX3, PAX7) located on chromosome 1 or 2 to the FKHR gene locus on chromosome 13 (Stegmaier et al., 2011). The PAX-FKHR fusion protein in ARMS maintains myogenic lineage but inhibits terminal myogenic differentiation through induction of MyoD and inhibition of cell cycle arrest (Graf Finckenstein, Shahbazian, Davicioni, Ren, & Anderson, 2007). Normal myogenic cells also express the PAX/FKHR mRNA, as well as other chimeric fusion mRNAs, during normal myogenesis, suggesting that a portion of this population of cells may become transformed during this process, producing ARMS tumors (Xie et al., 2016). ERMS tumors frequently display chromosomal abnormalities including aneuploidy and polyploidy, and are characterized by loss of heterozygosity on the short arm of chromosome 11 (Goldstein, Meller, Issakov, & Orr-Urtreger, 2006). Although the t(1 or 2;13) chromosome translocation is rare in ERMS, both PAX3 and PAX7 are frequently overexpressed in ERMS (Goldstein et al., 2006). PRMS also do not normally have the PAX-FKHR fusion and can have a highly complex karyotype, sometimes with abnormalities in every

chromosome (Goldstein et al., 2006). Similar to ERMS, PRMS tumors overexpress both PAX3 and FOXO1 (FKHR) (Goldstein et al., 2006).

Neither ARMS nor ERMS harbors many somatic mutations or genetic alterations (Shern et al., 2014), but tumors lacking the PAX-FKHR fusion protein tend to have a higher burden of somatic mutations in the TP53 and RB1 pathways (Xia, Pressey, & Barr, 2002). Interestingly, ERMS is proposed to originate at an earlier stage of myogenic development than ARMS (Stewart et al., 2018). Using whole-genome and transcriptomic sequencing, Seki et al. (Seki et al., 2015), further subdivide RMS to into four ARMS/ERMS subtypes based on somatic mutations: A1, A2, E1, and E2. While A1 and A2 show expression of PAX-FKHR and cell cycle regulators, the E1 and E2 subtypes contain mutations in the FGFR4/RAS/AKT pathways, as well as *PTEN* mutations (Seki et al., 2015). E1 and E2 also have greater chromosomal and epigenetic aberrations evidenced by changes in allelic imbalance and gene copy number (Seki et al., 2015).

Mutations in *TP53* in RMS range from 0.02% to 15% (Ognjanovic et al., 2012; Seki et al., 2015; Taylor et al., 2000), while amplification of *MDM2* is detected at less than 10% of RMS (Ognjanovic, Martel, et al., 2012, Seki et al., 2015, Taylor et al., 2000). Because ARMS rarely shows inactivation or mutations of TP53, other mechanisms may be responsible for reduced wtp53 activity. One such mechanism may be the overexpression of PAX proteins or the PAX-FHKR oncoprotein, since these proteins repress wtp53 transcriptional activity in RMS (Stuart, Haffner, Oren, & Gruss, 1995). PAX3 specifically downregulates TP53 protein levels, but not transcription (Pani, Horal, & Loeken, 2002). Interestingly, PAX5 can directly inhibit *TP53* mRNA expression by binding to the *TP53* promoter, a trait shared by PAX2 and PAX8 (Stuart et al., 1995).

On the other hand, ERMS tissues and their derived cell lines have a relatively high frequency of mutations or aberrations in the TP53/MDM2 axis (Felix et al., 1992). Specifically, Seki et al. (Seki et al., 2015) reveal that the E2 subtype of ERMS has a high rate (>45%) of TP53 mutation or copy number loss of *TP53* (Seki et al., 2015). Also, metastases of ERMS have high levels of TP53 expression (Leuschner et al., 2003), and the presence of TP53 mutations significantly reduces survival of patients of the E1/E2 subtypes (Seki et al., 2015). Intriguingly, in a *kRAS^{G12D}*-induced zebrafish ERMS model, deletion of *TP53* enhances invasion and metastasis (Ignatius et al., 2018), while expression of a dominant-negative mutp53 in mouse MSCs expressing PAX-FKHR fusion protein is sufficient to induce ARMS tumors in mice (Ren et al., 2008). Thus, although clinical relevance of TP53 appears not to be robust, TP53 and its upstream regulators may contribute to malignant progression of RMS, in specific subtypes or cellular contexts. Additionally, DNp73, the N-terminal deleted dominant-negative form of a TP53 family member, is frequently overexpressed in RMS (>80%) and is also shown to inhibit myogenic differentiation and contribute to transformation of mouse myoblast cells and RMS progression *in vivo* (Cam et al., 2006).

As mentioned above, prognosis of recurrent or metastatic RMS remains poor, and new treatment strategies should be developed (Shern et al., 2014). CP-31398, a small molecule drug which enhances wtp53 activity and restores wtp53 function from mutp53, is shown to induce ROS-dependent cell cycle arrest and apoptosis in wtp53-carrying A204 and mutp53-expressing ERMS cell lines to reduce their tumor growth in xenograft mouse models (Xu et al., 2010). Given that ARMS and PRMS rarely have TP53 mutations, compounds that restore wtp53 activity would also be efficient. On the other hand, for ERMS which often carries TP53 mutations, reactivating wtp53 activity from mutp53 may be an effective way to treat patients.

6. Leiomyosarcoma (LMS)

Leiomyosarcoma (LMS) is a soft tissue sarcoma arising *from* the smooth muscle cells lining small blood vessels (Danielson et al., 2010; Rubio et al., 2010). LMS most frequently occurs in the uterus (ULMS) but also arises in the abdomen, retroperitoneum, and large blood vessels

(non-uterine LMS) (Beck et al., 2010, Bleeker, Quevedo, & Folpe, 2012, Guo et al., 2015). Although ULMS is considered distinct from non-uterine LMS, these two types are genetically more similar to one another than other sarcomas (Abeshouse et al., 2017; Miettinen & Fetsch, 2006). Individuals with LFS or the condition called hereditary leiomyomatosis and renal cell carcinoma (HLRCC) have a higher risk of developing LMS (Farid & Ngeow, 2016). Another risk factor for ULMS is tamoxifen exposure for unrelated conditions, such as breast cancer (Bleeker et al., 2012). The prognosis for ULMS is worse than for other LMS, with a recurrence rate between 53%–71%, and the five-year overall survival for these patients is 15%–25% (D'Angelo & Prat, 2010). On the other hand, 39% of non-uterine LMS patients experience recurrence either locally or distantly, with retroperitoneal LMS cases having a higher recurrence rate of 51% (Gladdy et al., 2013). The five-year overall survival for non-uterine LMS is 64% (Mankin et al., 2004). The first line chemotherapy for LMS is presently a combination of gemcitabine and docetaxel (Momtahen, Curtin, & Mittal, 2016; Seddon et al., 2017); however, a recent study suggests that doxorubicin may have better outcomes in combination with gemcitabine than docetaxel (Seddon et al., 2017).

Unlike other sarcomas, LMS does not have a key fusion protein driving its tumorigenesis, although a small group of ULMS (<2.5%) is found to express an ALK fusion protein (KANK2-ALK, ACTG2-ALK) (Davis et al., 2019). Rather, the general molecular alterations in LMS affect activities of the tumor suppressors TP53, PTEN, and/or RB1 with deletion of *PTEN* and *RB1* and mutations of *TP53* (Chudasama et al., 2018; Grossmann, Layfield, & Randall, 2012; Gunderson et al., 2016; Yang et al., 2009). Cytogenetic studies of LMS suggest that loss of tumor suppressors can be an initiating event in LMS, while oncogene activation may occur at a later stage of malignant progression, because low-grade tumors contain more DNA copy number losses, while high-grade tumors have more copy number gains (Grossmann et al., 2012). Interestingly, loss of TP53, but not RB1, is sufficient to transform MSCs and induce LMS formation in mice (Rubio et al., 2010). Besides these tumor suppressors, LMS often has mutations in *ATRX* (Alpha thalassemia/mental retardation syndrome X-linked) with a mutation rate of ~30% in ULMS (Gunderson et al., 2016; Mäkinen et al., 2016). ATRX is a SWI/SNF chromatin remodeling protein which acts as a tumor suppressor (Kadoch & Crabtree, 2015). ULMS also harbors mutations in *MED12* (mediator complex subunit 12), a coactivator involved in the interaction of transcription factors with RNA polymerase II, at a ~20% frequency, but this does not occur in non-uterine LMS (Mäkinen et al., 2016; Mäkinen, Kämpjärvi, Frizzell, Bützow, & Vahteristo, 2017). *MED12* mutation is also common in the benign tumor leiomyoma (Ravegnini et al., 2012), suggesting that ULMS harboring *MED12* mutations may represent the small population of tumors known to originate from leiomyoma (Mäkinen et al., 2017). Intriguingly, ULMS tumors frequently have one or more hallmarks of "BRCAness", enabling the use of a PARP inhibitor for ULMS treatment (Chudasama et al., 2018; Seligson et al., 2018).

TP53 is mutated in ~50% of all LMS and ~35% of ULMS (Abeshouse et al., 2017; Gao, Seebacher, Hornicek, Guo, & Duan, 2018; O'neill, McBride, Connolly, & McCluggage, 2007). LMS frequently shows gene amplifications near the gene locus of *MDM2*, 12q15 (Ragazzini et al., 2004); however, *MDM2* amplification is rare in LMS (Miura et al., 2012; Miyajima et al., 2001; Yang et al., 2009). Importantly, there is a correlation between abnormalities in *TP53* and an advanced clinicopathological stage or poor prognosis in LMS (Konomoto, Fukuda, Hayashi, Kumazawa, & Tsuneyoshi, 1998; Patterson et al., 1994), suggesting potential value for TP53-targeting therapies. Indeed, a mutp53 reactivator, PRIMA-1, is shown to reduce viability of IB134 ULMS and IB138 soft tissue LMS cell lines harboring *TP53* mutations, while it is less effective in the wtp53-expressing IB139 LMS cell line (Grellety et al., 2015). Also, Gendicine, a recombinant adenoviral vector expressing wtp53, is clinically used in China and shows a 66.7% remission rate and a 91.7% responsive rate in combination with chemotherapy in ULMS (Xia, Du, Wang, & Li, 2018, Zhang et al., 2018). These results

support the idea that restoring wtp53 activity in tumors may be beneficial for LMS patients.

7. Synovial sarcoma

Synovial sarcoma comprises up to 10% of all soft tissue sarcomas and is the second most common soft tissue sarcoma in patients younger than 30 years old, although the majority (70%) of patients are older than 30 years old (Murphey et al., 2006, Stacchiotti & Van Tine, 2017). The prognosis of synovial sarcoma is worse with increased age (Jang et al., 2007; Stacchiotti & Van Tine, 2017). Tumors frequently occur in the lower half of the body, particularly near the knee joint, but can occur in the head and neck areas of the upper body (Gopalakrishnan et al., 2017, Murphey et al., 2006). MSCs are thought to be the cell of origin for synovial sarcoma (Garcia et al., 2012, Norifumi Naka et al., 2010). Tumors have the appearance of synovial tissue, but are unrelated to the synovium, and they are comprised of two main cell types: epithelial cells and mesenchymal spindle cells (El Beaino, Araujo, Lazar, & Lin, 2017, Murphey et al., 2006). The presence of one or both of these cell types as well as the degree of cellular differentiation defines the sarcoma's subtype: monophasic (mesenchymal), biphasic (epithelial and mesenchymal), and small cell (poorly differentiated) (El Beaino et al., 2017). Importantly, over half (50–70%) of synovial sarcomas metastasize, which makes overall survival for synovial sarcoma less than 40% (Krieg et al., 2011).

A recent whole-genome sequencing analysis has revealed that 95% of synovial sarcomas express the fusion oncoprotein SS18 (synovial sarcoma translocation, chromosome 18)-SSX, making it a defining characteristic of synovial sarcoma (Vlenterie et al., 2015). The t(X:18)(p11.2; q11.2) chromosomal translocation creates an in-frame fusion of SS18 to SSX1, SSX2, or SSX4, leading to generation of a SS18-SSX protein (Clark et al., 1994; de Leeuw, Balemans, Weghuis, & van Kessel, 1995; Skytting et al., 1999). Although the SS18-SSX lacks a DNA binding domain, it interacts with other chromatin regulators, including components of the SWI/SNF complex (e.g., hBRM, BRG1), to act as an oncoprotein that drives synovial sarcoma progression (Clark et al., 1994; de Leeuw et al., 1995; Skytting et al., 1999). To support this, SS18-SSX proteins have been found to bind with a non-canonical polycomb repressive complex 1 (PRC1.1) and co-associate with SWI/SNF and KDM2B complexes to aberrantly regulate the expression of developmentally regulated transcription factors and mesenchymal differentiation genes (Banito et al., 2018). Additionally, SS18-SSX plays roles in activation of the WNT/β-catenin and PI3K/AKT pathways and stabilization of MDM2, leading to inhibition of TP53 activity (Arcy, Maruwge, Ryan, & Brodin, 2008; Bozzi et al., 2008).

Synovial sarcomas do not frequently display mutations in the TP53 gene (D'Arcy, Ryan, & Brodin, 2009). Despite its low rate of mutations (~6%), TP53 alteration may be an effective prognostic indicator because tumors with missense mutations in the TP53 gene show significantly reduced 5-year survival when compared to non-mutated tumors (Schneider-stock et al., 1999). Also, over 3-fold gene amplifications of MDM2 and MDM4 are observed in 33% and 44% of synovial sarcoma tissues, respectively, which has an inverse correlation with TP53 mutations (Ito et al., 2011). This is supported by the finding of that SS18-SSX1 induces TP53 degradation by MDM2 (Arcy et al., 2008). Thus, TP53 activity appears to be lowered in synovial sarcoma through MDM2/MDM4.

Presently, synovial sarcomas are treated with doxorubicin, ifosfamide, and pazopanib, a multi-targeted tyrosine kinase inhibitor, in addition to surgical resection (In, Hu, & Tseng, 2017). These therapies are mainly effective to non-metastatic synovial sarcoma but have limited effectiveness in tumors with metastases. Hence, the overall 10-year survival rates are 50-60% (Lewis et al., 2000). Obviously, new therapeutic strategies must be developed for metastatic synovial sarcomas. Since TP53 mutation is uncommon in synovial sarcoma, restoration of wtp53 activity in tumors by MDM2/MDM4 inhibitors may be a rational strategy for this type of sarcoma. Indeed, Nutlin-3a and MI-219, two small molecule inhibitors of MDM2, are shown to inhibit the growth of synovial sarcoma cells in vitro (Banito et al., 2018; D'Arcy et al., 2009; Wade, Li, & Wahl, 2013).

8. Liposarcoma (LPS)

Liposarcoma (LPS) is the most common adult soft tissue sarcoma and represents ~25% of all soft tissue sarcomas. It is a tumor derived from the mesenchymal adipogenic lineage, and most commonly arises in the limbs, retroperitoneum, and the paratesticular areas of the body (Brill et al., 2010; Bui et al., 2011; Peng et al., 2011). LPS is often confused for a benign tumor (Dodd, 2012), posing a threat for patient care. There are four key subtypes of LPS which have been identified based on cytogenetic features: myxoid/round cell LPS, pleomorphic LPS, well-differentiated LPS, and de-differentiated LPS (Bui et al., 2011; Genadry, Pietrobono, Rota, & Linardic, 2018). The subtypes can be distinguished by the presence of the FUS-CHOP fusion oncoprotein (myxoid/round cell LPS), MDM2 overexpression (well-differentiated, and de-differentiated LPS), and chromosomal abnormalities (pleomorphic LPS) (L. G. Dodd, 2012). LPS has about a 20% rate of recurrence overall, with de-differentiated LPS showing a higher local recurrence rate of 37.6% (Vos et al., 2018). Distant metastasis occurs in ~20% of all LPS, while in the pleomorphic subtype metastasis occurs in ~45% of tumors (Vos et al., 2018). Although LPS has a relatively good prognosis overall with a five-year overall survival rate of ~80%, de-differentiated and pleomorphic LPS show significantly worse prognosis with overall 5-year survival rates at ~40% (Ng, Scharschmidt, Mayerson, & Fisher, 2013; Vos et al., 2018). Pleomorphic LPS also tends to have highly variable karyotypes (Mandahl et al., 2017).

A chromosomal translocation t(12;16)(q13;p11) results in the creation of a fusion oncoprotein, FUS-CHOP (also referred to as TLS-CHOP), which is present in myxoid/round cell LPS but not in other types (Rodriguez et al., 2011; Tornin et al., 2018). In rare cases, t(12;22)(q13;q12) translocation creates the EWS-CHOP fusion protein (Rodriguez et al., 2011). FUS is an RNA-binding protein involved in regulation of gene expression, genomic integrity, and mRNA/microRNA processing, while CHOP is an ER-stress response transcription factor (Nishitoh, 2011). Overexpression of FUS-CHOP in the mouse genome under the human EF1α promoter is shown to induce LPS in 100% of mice (Pérez-Losada et al., 2000). LPS tumors developed in FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARγ (Pérez-Losada et al., 2000). FUS-CHOP–overexpressing primary mesenchymal progenitor cells (MPC) also form tumors resembling human myxoid LPS (Riggi et al., 2006). Transcription profile analysis of these tumors and non-xenografted MPCs expressing FUS-CHOP reveals repression of CTGF, PERP, and TFPI, as well as induction of growth factors (PDGFA, HGF), cytokines (IL6), growth factor receptors (MET), cell cycle regulators (CDK4, MDM2), proteolytic enzymes (MMP-11, CTSD, PLAT), and adipocyte differentiation-associated factors, (ADFP, FASN, HMGCR, RGS2) (Riggi et al., 2006). Moreover, the FUS-CHOP fusion protein enhances invasiveness of LPS cells by activating the SRC/FAK/RHO/ROCK pathway, and enhances metastatic potential of LPS cells by transcriptionally upregulating MMP2 proteases (Patil et al., 2014; Tornin et al., 2018).

Intriguingly, supernumerary ring chromosomes and giant rod marker chromosomes are observed in myxoid/round cell, well-differentiated, and de-differentiated LPS (Laroche-Clary et al., 2017; Macchia et al., 2018; Mandahl et al., 2017; Pedeutour et al., 1999). These supernumerary chromosomes frequently amplify the CDK4, HMGA2, and MDM2 genes from chromosome 12q (Mandahl et al., 2017; Pedeutour et al., 1999; Szymanska et al., 1996). Also, well-differentiated and de-differentiated LPSs carry neochromosomes due to amplifications and rearrangements of chromosome 12q encoding oncogenes (MDM2, CDK4, YEATS2) and adipocytic differentiation factors (HMGA2, CPM) (Beird et al., 2018). A recent study with exome and

RNA sequencing analyses using 17 patients with both well-differentiated and de-differentiated LPSs reveals that the two subtypes share only 8.3% of their somatic mutations between matched tumors, suggesting the possibility that these tumors arise from a common origin and diverge at an early stage of tumor development (Beird et al., 2018). Moreover, de-differentiated tumors show greater genomic instability attributed to an early clonal divergence from well-differentiated LPS tumors (Beird et al., 2018).

An earlier study by Barretina et al. (2010) identify mutations in *TP53* and *NF1*, as well as *PIK3CA* mutations in myxoid/round-cell LPSs. To support their finding, SNP arrays, whole exome sequencing, and targeted exome sequencing by Kanojia et al. (2015) identify *carboxypeptidase M* (*CPM*), which cleaves C-terminal arginine or lysine residues from polypeptides, as an oncogene which is involved in the EGFR pathway and is recurrently amplified in well-differentiated and de-differentiated LPS. They also report *FGFR1* amplification at chromosome 8p11.23, classical *CDK4*, *HMGA2*, and *MDM2* amplification at the chromosome 12q13-15 region, and deletion of *TP53BP1* at chromosome 15q15 in de-differentiated LPS. Moreover, their functional analyses reveal the tumor suppressive role of neurofibromin 1 (NF1), which negatively regulates RAS through hydrolysis of RAS-GTP, in LPS, irrespective of subtype (Kanojia et al., 2015).

Mutations in *TP53* are not usually high in LPS (10–20%), except for pleomorphic LPS, in which ~60% of cases show *TP53* mutations. This is likely because the *MDM2* gene is amplified in the majority of well-differentiated and de-differentiated LPSs, leading to functional inactivation of TP53 without mutations (Abeshouse et al., 2017; Barretina et al., 2010; Ghadimi et al., 2011; Kawai et al., 1994; Nakayama et al., 1995; Taubert et al., 1998). However, mutations in *TP53* are associated with proliferation, tumor aggressiveness, reduced patient survival, and advanced disease in LPS (Antonescu et al., 2001; Kawai et al., 1994; Schneider-Stock et al., 1999). Moreover, subcutaneous transplantation of mouse adipose-derived mesenchymal stem/stromal cells (ASCs) expressing FUS-CHOP results in formation of LPS-like tumors only when cells are null for *TP53*, although this is not observed in human ASCs (Rodriguez et al., 2011). Since *TP53*-null mouse ASCs develop LMS, these data may indicate that FUS-CHOP predisposes *TP53*-null mouse ASCs to adipogenic differentiation (Rodriguez et al., 2011). To support this finding, Charytonowicz et al. (2012) generate a mouse model expressing *FUS-CHOP* specifically in mesoderm tissues. Although the *FUS-CHOP* transgenic mice are not tumor-prone, mice show development of sarcoma resembling myxoid/round cell LPS upon deletion of the *TP53* allele(s). Clinically, *TP53* mutations are detected in 15-30% of cases of human myxoid/round cell LPS and are correlated with unfavorable outcomes (Antonescu et al., 2001; Dei Tos et al., 1997; Schneider-Stock et al., 1999). Thus, FUS-CHOP and TP53 loss may have cooperative effects on myxoid round cell LPS progression.

Chemotherapeutic drugs for primary and metastatic LPS include doxorubicin and ifosfamide in the first-line setting, and other drugs including docetaxel and gemcitabine are also used (Kollár & Benson, 2014). However, due to high frequency of *MDM2* amplification and low frequency of *TP53* mutations in LPS, especially in well-differentiated and de-differentiated LPS, use of MDM2 antagonists to restore TP53 activity (e.g., Nutlin-3a, RG7112, SAR405838) can be a major therapeutic strategy (Ray-Coquard et al., 2012). Nutlin-3a has been extensively studied in multiple cancers, including in *MDM2*-amplified LPS cells, to restore wtp53 activity and induce apoptosis (Muller et al., 2007). A Nutlin-3a analog, RG7112, has been clinically tested for the treatment of patients with well-differentiated or de-differentiated LPS (Obrador-Hevia et al., 2015; Ray-Coquard et al., 2012). Although RG7112 stabilizes disease progression in many cases, it has significant adverse effects including neutropenia and thrombocytopenia, in as many as 40% of patients (Ray-Coquard et al., 2012). SAR405838 is also shown to inhibit de-differentiated LPS progression in *in vitro* and *in vivo* mouse models; it induces stabilization of TP53, upregulation of TP53 targets, and induction of apoptosis in de-differentiated LPS,

which has enabled this drug to enter early-phase clinical trials for multiple malignancies (Bill et al., 2016). As stated above, *TP53* mutation status is correlated with recurrence, metastasis, and advanced stage of LPS (Antonescu et al., 2001; Kawai et al., 1994; McGovern, Zhou, & Jones, 2017; Schneider-Stock et al., 1999). Hence, mutp53-targeted therapies may be efficacious for these aggressive LPS, which should be tested clinically in the future.

9. Angiosarcoma

Angiosarcomas are malignant endothelial-cell tumors originating from vascular or lymphatic tissues (Young, Brown, Reed, Hughes, & Woll, 2010). Angiosarcomas can occur spontaneously or secondarily to ionizing radiation or chronic lymphedema; they are subdivided into cutaneous, lymphoedema-associated, radiation-induced, primary-breast, and soft-tissue types (Behjati et al., 2014; Young et al., 2010). Surgical resection followed by high-dose radiotherapy is the standard of care. However, recurrence is frequent, and most patients ultimately develop metastases, leading to poor prognosis (Florou & Wilky, 2018). Tyrosine kinase inhibitors and vascular-targeted therapies can be efficacious, but some patients still develop drug resistance (Florou & Wilky, 2018; Spiker & Ramsey, 2018; Young et al., 2010). Better understanding of the molecular mechanisms of angiosarcoma malignancy is essential for discovery of new treatments and improvement of current therapeutic regimens.

Analyses of whole-genome, exome, and targeted sequencing with primary and secondary angiosarcomas have provided useful information in determining the potential causes of tumorigenesis. Behjati et al. (Behjati et al., 2014) identify recurrent mutations of angiogenesis-related genes, *PTPRB* (*receptor-type tyrosine-protein phosphatase β*) and *PLCG1* (*phospholipase C, γ1*) in angiosarcomas. The *PTPRB* gene has predominantly truncating mutations in 26% of tumors, with an activating R707Q missense mutation in 9% of cases (Behjati et al., 2014). Also, Murali et al. (Murali et al., 2015) report that more than 50% of angiosarcomas carry some genetic alterations impacting the MAPK pathway. These include mutations in *KRAS*, *HRAS*, *NRAS*, *BRAF*, *MAPK1*, and *NF1*, as well as amplifications in *MAPK1/CRKL*, *CRAF*, or *BRAF*. Moreover, the most frequently detected genetic aberrations are mutations in *TP53* (35%) and losses of *CDKN2A* (26%). *MYC* amplifications are detected in the majority (88%) of radiation-induced angiosarcomas, which is mutually exclusive of alterations in *TP53* and *CDKN2A*. Additionally, *FLT4* amplifications and mutations or rearrangements of *PTPRB*, *PLCG1*, *CIC*, *FLT4*, and *KDR* genes are detected in angiosarcomas (S. C. Huang et al., 2016). Thus, whole-genome sequencing analyses further confirm the molecular heterogeneity of angiosarcomas.

The involvement of TP53 in angiosarcomas is also shown by Naka et al. (1997), where frequency of *TP53* mutations is dependent on the site of tumors with an overall occurrence of ~50%. In addition to TP53 mutations, upregulation of MDM2 is reported in two-thirds of angiosarcoma cases (Zietz et al., 1998). Intriguingly, increased VEGF levels are observed in ~80% of cases, which is correlated with increased protein levels of TP53 and MDM2 (Zietz et al., 1998). The involvement of TP53 in angiosarcoma is also shown by mouse studies showing occurrence of angiosarcoma in *TP53* knockout mice (Landuzzi et al., 2014; Lang et al., 2004). Specifically, over 65% of alymphocytic *TP53* knockout mice (*Rag2*$^{-/-}$;*Il2rg*$^{-/-}$;*TP53*$^{-/-}$, referred to as *RGKO-TP53*$^{-/-}$) spontaneously develop hemangiosarcoma (Landuzzi et al., 2014). Furthermore, Li et al. (2014) observe that ~34% of mice carrying hypomorphic *TP53* alleles with overexpression of MDM2 (*MDM2*^{Tg} *TP53*$^{Neo/Neo}$) spontaneously develop angiosarcoma. Moreover, cre-mediated restoration of wtp53 expression in angiosarcoma developed in *MDM2*^{Tg} *TP53*$^{Neo/Neo}$ mice results in inhibition of tumor growth in a syngeneic transplant model, suggesting that TP53 restoration is a potential therapeutic strategy for angiosarcomas (Li et al., 2014). Considering the high frequency of TP53 mutations in angiosarcoma, TP53-targeted therapies may be an option for anti-angiosarcoma treatment. Meanwhile,

continuous efforts to understand the genetic heterogeneity of angiosarcomas and the identification of molecular targets for each subtype of angiosarcoma are necessary to determine the best therapy for each subtype (Florou & Wilky, 2018).

(Mehren & Joensuu, 2018)

10. Undifferentiated pleomorphic sarcoma (UPS)

Undifferentiated pleomorphic sarcoma (UPS) is an aggressive bone and soft tissue sarcoma, originally called malignant fibrous histiocytoma and later reclassified as UPS in 2002 by the World Health Organization (WHO) (Matushansky et al., 2009, Murphey, 2007). UPS is categorized to four subtypes based on the histology: storiform-pleomorphic, myxoid, giant cell, and inflammatory types. The storiform-pleomorphic type is the most common (~70%), followed by the myxoid variant (~20%), while giant cell and inflammatory types are rare. Of these subtypes, the myxoid variant is the least aggressive and has the best prognosis. Most patients are between 50 and 70 years old, and the most common tumor location is the lower extremities (Dei Tos, 2006, Murphey, 2007).

Due to clinical and genetic heterogeneity, few studies have analyzed the molecular profiles of UPS (Dodd, 2016). Conventional comparative genomic hybridization (CGH) and gene expression profiling analyses reveal similarity between UPS and LMS including loss of 13q14-21 as the most common deletion and alterations of the RB and TP53 pathways (Carneiro et al., 2009). Using Ptch1, TP53 and/or RB1 conditional knock-out mouse models, Rubin et al. (Rubin et al., 2011) show that ERMS and UPS are a continuum of myodifferentiation, with satellite cells giving rise to UPS. Also, loss of RB1, but not TP53, promotes undifferentiated phenotypes to mimic UPS (Rubin et al., 2011). However, recent multi-platform molecular landscape analyses using human soft tissue sarcomas identify molecular similarity between UPS and myxofibrosarcoma and suggest the involvement of the Hippo pathway in UPS pathogenesis (Cancer Genome Atlas Research Network. Electronic address & Cancer Genome Atlas Research Network. Electronic address, E. D. S. C, and Cancer Genome Atlas Research, N., 2017). Moreover, some previously diagnosed peripheral UPSs, which do not have characteristics of well-differentiated LPS but have MDM2 gene amplifications, later turned out to be de-differentiated LPS (Le Guellec et al., 2014). Overall, due to complex molecular heterogeneity and difficulty of diagnosis, the genetic and molecular profiling of UPS remains unclear. Nonetheless, Serrano et al. (Serrano et al., 2016) recently show that the RAS/MAPK and PI3K/mTOR pathways are activated in the majority of cases of UPS, while activation of the RAS/MAPK pathway is correlated with an increased risk of disease recurrence and impaired overall survival (Dodd, 2016).

Regarding the involvement of TP53 in UPS, a study using a large series of 143 soft tissue sarcomas identifies genomic deletion of the TP53 locus in 18.4% of tumors and TP53 mutations in 32% (Perot et al., 2010). Intriguingly, most UPS (87.2%) retain one wild-type TP53 allele. Furthermore, most tumors which do not have TP53 alterations show deletion or silencing of the p14ARF gene, a negative regulator of MDM2 (Perot et al., 2010). These results suggest that the p14ARF-MDM2-p53 pathway plays crucial roles in UPS pathogenesis. Hence, restoring wtp53 activity may be one option for treating UPS.

11. Conclusions and future perspectives

In this review we have summarized the role of TP53 in bone and soft tissue sarcomas with emphasis on TP53 and mutations/deletions in TP53 as therapeutic targets. Alterations to TP53 or other genes in the TP53 pathway often occur in sarcomas. Notably, over 70% of osteosarcoma has structural variants or mutations in the TP53 gene, Ewing sarcoma is rarely mutated for TP53 due to EWS-FLI1's inhibitory effect on TP53, non-uterine LMS has a high rate (~50%) of TP53 mutation, and well- and de-differentiated LPSs are defined by amplification of

MDM2. Evolving new technologies, including next generation sequencing, would enable identification of novel therapeutic targets, some of which may directly or indirectly alter TP53 activity. While current TP53-targeted therapies have some drawbacks in a clinical setting, including bone marrow suppression and other side effects, improved TP53-targeted therapies to restore wtp53 activity, reactivate wtp53 activity from mutp53, deplete mutp53, and target vulnerabilities in TP53-mutated/deleted cells may prove effective in therapy-resistant bone and soft tissue sarcomas in the near future.

Declarations of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

References

Abeshouse, A., Adebamowo, C., Adebamowo, S. N., Akbani, R., Akeredolu, T., Ally, A., ... Zmuda, E. (2017). Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965 (e928).

Abraham, J., Nuñez-Álvarez, Y., Hettmer, S., Carrió, E., Chen, H. -I. H., Nishijo, K., ... Keller, C. (2014). Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes & Development 28, 1578–1591.

Abudu, A., Mangham, D. C., Reynolds, G. M., Pynsent, P. B., Tillman, R. M., Carter, S. R., & Grimer, R. J. (1999). Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. British Journal of Cancer 79, 1185–1189.

Adhikari, A. S., & Iwakuma, T. (2009). Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi 100, 217–228.

de Alava, E., Antonescu, C. R., Panizo, A., Leung, D., Meyers, P. A., Huvos, A. G., ... Ladanyi, M. (2000). Prognostic impact of P53 status in Ewing sarcoma. Cancer 89, 783–792.

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., ... Moll, U. M. (2015). Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356.

Al-Romaih, K., Bayani, J., Vorobyova, J., Karaskova, J., Park, P. C., Zielenska, M., & Squire, J. A. (2003). Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genetics and Cytogenetics 144, 91–99.

Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., ... Flanagan, A. M. (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. The Journal of Pathology 224, 334–343.

Anderson, N. D., de Borja, R., Young, M. D., Fuligni, F., Rosic, A., Roberts, N. D., ... Shlien, A. (2018). Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science 361.

Antonescu, C. R., Tschernyavsky, S. J., Decuseara, R., Leung, D. H., Woodruff, J. M., Brennan, M. F., ... Ladanyi, M. (2001). Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clinical Cancer Research 7, 3977–3987.

Arcy, P., Maruwge, W., Ryan, B. A., & Brodin, B. (2008). The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Molecular Cancer Research 6, 127.

Aryee, D. N., Niedan, S., Ban, J., Schwentner, R., Muehlbacher, K., Kauer, M., ... Kovar, H. (2013). Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. British Journal of Cancer 109, 2696–2704.

Asada, N., Tsuchiya, H., & Tomita, K. (1999). De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Research 19, 5131–5137.

Asp, J., Sangiorgi, L., Inerot, S. E., Lindahl, A., Molendini, L., Benassi, M. S., & Picci, P. (2000). Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. International Journal of Cancer 85, 782–786.

Balamuth, N. J., & Womer, R. B. (2010). Ewing's sarcoma. The Lancet Oncology 11, 184–192.

Ban, J., Bennani-Baiti, I. M., Kauer, M., Schaefer, K. L., Poremba, C., Jug, G., ... Kovar, H. (2008). EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Research 68, 7100–7109.

Banito, A., Li, X., Laporte, A. N., Roe, J. -S., Sanchez-Vega, F., Huang, C. -H., ... Lowe, S. W. (2018). The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell 33, 527–541 (e528).

Bardot, B., & Toledo, F. (2017). Targeting MDM4 splicing in cancers. Genes (Basel) 8.

Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., ... Singer, S. (2010). Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics 42, 715.

Beck, A. H., Lee, C. H., Witten, D. M., Gleason, B. C., Edris, B., Espinosa, I., ... van de Rijn, M. (2010). Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29, 845–854.

Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., ... Campbell, P. J. (2017). Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications 8, 15936.

Behjati, S., Tarpey, P. S., Sheldon, H., Martincorena, I., Van Loo, P., Gundem, G., ... Campbell, P. J. (2014). Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics 46, 376–379.

Beird, H. C., Wu, C. -C., Ingram, D. R., Wang, W. -L., Alimohamed, A., Gumbs, C., ... Roland, C. L. (2018). Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Molecular Case Studies 4, a002386.

Bill, K. L. J., Garnett, J., Meaux, I., Ma, X., Creighton, C. J., Bolshakov, S., ... Pollock, R. E. (2016). SAR405838: A novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clinical Cancer Research 22, 1150.

Binayke, A., Mishra, S., Suman, P., Das, S., & Chander, H. (2019). Awakening the "guardian of genome": reactivation of mutant p53. Cancer Chemotherapy and Pharmacology 83, 1–15.

Bista, M., Smithson, D., Pecak, A., Salinas, G., Pustelny, K., Min, J., ... Guy, R. K. (2012). On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS ONE 7, e37518.

Blasenbreu, S., Baretton, G. B., Bender, C., Haas, C. J., Diebold, J., & Lohrs, U. (1998). TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression. Verhandlungen der Deutschen Gesellschaft für Pathologie 82, 284–289.

Bleeker, J. S., Quevedo, J. F., & Folpe, A. L. (2012). "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies. Sarcoma 2012 (541626-541626).

Bovee, J. V., Hogendoorn, P. C., Wunder, J. S., & Alman, B. A. (2010). Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews. Cancer 10, 481–488.

Bozzi, F., Ferrari, A., Negri, T., Conca, E., Luca, D. R., Losa, M., ... Pilotti, S. (2008). Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Translational Oncology 1, 95–101.

Bridge, J. A., Bhatia, P. S., Anderson, J. R., & Neff, J. R. (1993). Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genetics and Cytogenetics 69, 79–90.

Brill, E., Gobble, R., Angeles, C., Lagos-Quintana, M., Crago, A., Laxa, B., ... Singer, S. (2010). ZIC1 overexpression is oncogenic in liposarcoma. Cancer Research 70, 6891–6901.

Brohl, A. S., Patidar, R., Turner, C. E., Wen, X., Song, Y. K., Wei, J. S., ... Khan, J. (2017). Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genetics in Medicine 19, 955–958.

Brohl, A. S., Solomon, D. A., Chang, W., Wang, J., Song, Y., Sindiri, S., ... Khan, J. (2014). The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genetics 10, e1004475.

Bui, B., Lortal, B., Toulmonde, M., Italiano, A., Antonescu, C. R., Singer, S., ... Blay, J. -Y. (2011). Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Annals of Oncology 23, 1601–1607.

Burchill, S. A. (2003). Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. Journal of Clinical Pathology 56, 96–102.

Bykov, V. J., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., ... Wiman, K. G. (2005). Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. The Journal of Biological Chemistry 280, 30384–30391.

Bykov, V. J., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005). PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24, 3484–3491.

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018). Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer 18, 89–102.

Cam, H., Griesmann, H., Beitzinger, M., Hofmann, L., Beinoraviciute-Kellner, R., Sauer, M., ... Stiewe, T. (2006). p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10, 281–293.

Cancer Genome Atlas Research Network. Electronic address, E. D. S. C, & Cancer Genome Atlas Research, N (2017). Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171(950-965), e928.

Carneiro, A., Francis, P., Bendahl, P. O., Fernebro, J., Akerman, M., Fletcher, C., ... Nilbert, M. (2009). Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Laboratory Investigation 89, 668–675.

Charytonowicz, E., Terry, M., Coakley, K., Telis, L., Remotti, F., Cordon-Cardo, C., ... Matushansky, I. (2012). PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. The Journal of Clinical Investigation 122, 886–898.

Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., ... St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome, P (2014). Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Reports 7, 104–112.

Chen, Z., Guo, J., Zhang, K., & Guo, Y. (2016). TP53 mutations and survival in osteosarcoma patients: a meta-analysis of published data. Disease Markers 2016, 4639575.

Cheok, C. F., Dey, A., & Lane, D. P. (2007). Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Molecular Cancer Research 5, 1133–1145.

Chow, W. A. (2018). Chondrosarcoma: Biology, genetics, and epigenetics. F1000Res 7.

Chudasama, P., Mughal, S. S., Sanders, M. A., Hubschmann, D., Chung, I., Deeg, K. I., ... Frohling, S. (2018). Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications 9, 144.

Chung, S. W., Kim, G. C., Kweon, S., Lee, H., Choi, J. U., Mahmud, F., ... Byun, Y. (2018). Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment. Biomaterials 182, 35–43.

Clark, J., Rocques, P. J., Crew, A. J., Gill, S., Shipley, J., Chan, A. M. L., ... Cooper, C. S. (1994). Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genetics 7, 502.

Correa, H. (2016). Li-Fraumeni syndrome. Journal of Pediatrics Genetics 5, 84–88.

Crompton, B. D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K. C., Calicchio, M. L., ... Stegmaier, K. (2014). The genomic landscape of pediatric Ewing sarcoma. Cancer Discovery 4, 1326–1341.

D'Arcy, P., Ryan, B. A., & Brodin, B. (2009). Reactivation of p53 function in synovial sarcoma cells by inhibition of p53–HDM2 interaction. Cancer Letters 275, 285–292.

Dai, X., Ma, W., He, X., & Jha, R. K. (2011). Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Medical Science Monitor 17, RA177–RA190.

D'Angelo, E., & Prat, J. (2010). Uterine sarcomas: A review. Gynecologic Oncology 116, 131–139.

Danielson, L. S., Menendez, S., Attolini, C. S. -O., Guijarro, M. V., Bisogna, M., Wei, J., ... Hernando, E. (2010). A differentiation-based microRNA signature identifies Leiomyosarcoma as a mesenchymal stem cell-related malignancy. The American Journal of Pathology 177, 908–917.

Davis, L. E., Nusser, K. D., Przybyl, J., Pittsenbarger, J., Hofmann, N. E., Varma, S., ... Davare, M. A. (2019). Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma. Molecular Cancer Research 17, 676–685.

Dei Tos, A. P. (2006). Classification of pleomorphic sarcomas: where are we now? Histopathology 48, 51–62.

Dei Tos, A. P., Piccinin, S., Doglioni, C., Vukosavljevic, T., Mentzel, T., Boiocchi, M., & Fletcher, C. D. (1997). Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. The American Journal of Pathology 151, 1531–1539.

Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H., ... Guccione, E. (2016). Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. The Journal of Clinical Investigation 126, 68–84.

Di Conza, G., Buttarelli, M., Monti, O., Pellegrino, M., Mancini, F., Pontecorvi, A., ... Moretti, F. (2012). IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Molecular Cancer Therapeutics 11, 1247–1256.

Dijkhuizen, T., van den Berg, E., Molenaar, W. M., Oosterhuis, J. W., Dam, A., Wiersema, J., ... de Jong, B. (1994). Cytogenetics as a tool in the histologic subclassification of chondrosarcomas. Cancer Genetics and Cytogenetics 76, 100–105.

Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., ... Martinez, L. A. (2012). Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes & Development 26, 830–845.

Dobashi, Y., Sugimura, H., Sato, A., Hirabayashi, T., Kanda, H., Kitagawa, T., ... Machinami, R. (1993). Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagnostic Molecular Pathology 2, 257–263.

Dodd, L. G. (2012). Update on liposarcoma: A review for cytopathologists. Diagnostic Cytopathology 40, 1122–1131.

Dodd, R. D. (2016). Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma. Cancer 122, 17–19.

Duhamel, L. A., Ye, H., Halai, D., Idowu, B. D., Presneau, N., Tirabosco, R., & Flanagan, A. M. (2012). Frequency of mouse double minute 2 (MDM2) and mouse double minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 60, 357–359.

Duran, A., Linares, J. F., Galvez, A. S., Wikenheiser, K., Flores, J. M., Diaz-Meco, M. T., & Moscat, J. (2008). The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13, 343–354.

Egas-Bejar, D., & Huh, W. W. (2014). Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolescent Health, Medicine and Therapeutics 5, 115–125.

Eid, J. E., & Garcia, C. B. (2015). Reprogramming of mesenchymal stem cells by oncogenes. Seminars in Cancer Biology 32, 18–31.

El Beaino, M., Araujo, D. M., Lazar, A. J., & Lin, P. P. (2017). Synovial sarcoma: Advances in diagnosis and treatment identification of new biologic targets to improve multimodal therapy. Annals of Surgical Oncology 24, 2145–2154.

van der Ent, W., Jochemsen, A. G., Teunisse, A. F., Krens, S. F., Szuhai, K., Spaink, H. P., ... Snaar-Jagalska, B. E. (2014). Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. The Journal of Pathology 233, 415–424.

Esiashvili, N., Prabhu, R., Kahn, S., & Paulino, A. C. (2013). Current strategies and challenges in treatment of childhood rhabdomyosarcoma. Journal of Radiation Oncology 2, 159–168.

Fan, J., & Bertino, J. R. (1999). Modulation of cisplatinum cytotoxicity by p53: Effect of p53-mediated apoptosis and DNA repair. Molecular Pharmacology 56, 966–972.

Fan, L., Yin, S., Zhang, E., & Hu, H. (2018). Role of p62 in the regulation of cell death induction. Apoptosis 23, 187–193.

Farid, M., & Ngeow, J. (2016). Sarcomas associated with genetic cancer predisposition syndromes: A review. The Oncologist 21, 1002–1013.

Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., ... Helman, L. J. (1992). Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Research 52, 2243–2247.

Florou, V., & Wilky, B. A. (2018). Current and future directions for angiosarcoma therapy. Current Treatment Options in Oncology 19, 14.

Fu, H. L., Shao, L., Wang, Q., Jia, T., Li, M., & Yang, D. P. (2013). A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biology 34, 3817–3821.

Gao, P., Seebacher, N. A., Hornicek, F., Guo, Z., & Duan, Z. (2018). Advances in sarcoma gene mutations and therapeutic targets. Cancer Treatment Reviews 62, 98–109.

Garcia, C. B., Shaffer, C. M., Alfaro, M. P., Smith, A. L., Sun, J., Zhao, Z., ... Eid, J. E. (2012). Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. *Oncogene 31*, 2323–2334.

Gelderblom, H., Hogendoorn, P. C., Dijkstra, S. D., van Rijswijk, C. S., Krol, A. D., Taminiau, A. H., & Bovee, J. V. (2008). The clinical approach towards chondrosarcoma. *Oncologist 13*, 320–329.

Genadry, K. C., Pietrobono, S., Rota, R., & Linardic, C. M. (2018). Soft tissue sarcoma cancer stem cells: an overview. *Frontiers in Oncology 8* (475-475).

Gennari, L., Rendina, D., Falchetti, A., & Merlotti, D. (2019). Paget's disease of bone. *Calcified Tissue International 104*, 483–500.

Ghadimi, M. P., Liu, P., Peng, T., Bolshakov, S., Young, E. D., Torres, K. E., ... Lev, D. (2011). Pleomorphic liposarcoma. *Cancer 117*, 5359–5369.

Gladdy, R. A., Qin, L. -X., Moraco, N., Agaram, N. P., Brennan, M. F., & Singer, S. (2013). Predictors of survival and Recurrence in Primary Leiomyosarcoma. *Annals of Surgical Oncology 20*, 1851–1857.

Goiran, T., Duplan, E., Rouland, L., El Manaa, W., Lauritzen, I., Dunys, J., ... Alves da Costa, C. (2018). Nuclear p53-mediated repression of autophagy involves PINK1 transcriptional down-regulation. *Cell Death and Differentiation 25*, 873–884.

Gokgoz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001). Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. *Cancer 92*, 2181–2189.

Goldstein, M., Meller, I., Issakov, J., & Orr-Urtreger, A. (2006). Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. *Neoplasia 8*, 332–343.

Gopalakrishnan, V., Amini, B., Wagner, M. J., Nowell, E. N., Lazar, A. J., Lin, P. P., ... Araujo, D. M. (2017). Synovial sarcoma of the head and neck: a single institution review. *Sarcoma 2017* (2016752-2016752).

Goto, A., Kanda, H., Ishikawa, Y., Matsumoto, S., Kawaguchi, N., Machinami, R., ... Kitagawa, T. (1998). Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. *Japanese Journal of Cancer Research 89*, 539–547.

Graf Finckenstein, F., Shahbazian, V., Davicioni, E., Ren, Y. X., & Anderson, M. J. (2007). PAX-FKHR as pangenes by simultaneously inducing and inhibiting myogenesis. *Oncogene 27*, 2004.

Greditzer, H. G., 3rd, McLeod, R. A., Unni, K. K., & Beabout, J. W. (1983). Bone sarcomas in Paget disease. *Radiology 146*, 327–333.

Grellety, T., Laroche-Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., & Italiano, A. (2015). PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. *BMC Cancer 15* (684-684).

Grossmann, A. H., Layfield, L. J., & Randall, R. L. (2012). Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma. *Sarcoma 2012*.

Gruener, G., & Camacho, P. (2014). Paget's disease of bone. *Handbook of Clinical Neurology 119*, 529–540.

Grunewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Alava, E., Kovar, H., ... Dirksen, U. (2018). Ewing sarcoma. *Nature Reviews. Disease Primers 4*, 5.

Guerzoni, C., Fiori, V., Terracciano, M., Manara, M. C., Moricoli, D., Pasello, M., ... Scotlandi, K. (2015). CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. *Clinical Cancer Research 21*, 146–156.

Guha, T., & Malkin, D. (2017). Inherited TP53 mutations and the Li-Fraumeni syndrome. *Cold Spring Harbor Perspectives in Medicine*, 7.

Gunderson, C., McMahon, C., Elvin, J. A., Ross, J. S., Moore, K. N., Gay, L. M., ... Ramkissoon, S. (2016). Comprehensive genomic profiling of uterine leiomyosarcomas identifies opportunities for personalized therapies. *Annals of Oncology 27*.

Guo, W., Wang, X., & Feng, C. (1996). P53 gene abnormalities in osteosarcoma. *Chinese Medical Journal 109*, 752–755.

Guo, X., Jo, V. Y., Mills, A. M., Zhu, S. X., Lee, C. -H., Espinosa, I., ... van de Rijn, M. (2015). Clinically Relevant Molecular Subtypes in Leiomyosarcoma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21*, 3501–3511.

Gurpinar, E., & Vousden, K. H. (2015). Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation. *Trends in Cell Biology 25*, 486–495.

Hameed, M., Ulger, C., Yasar, D., Limaye, N., Kurvathi, R., Streck, D., ... Toruner, G. A. (2009). Genome profiling of chondrosarcoma using oligonucleotide array-based comparative genomic hybridization. *Cancer Genetics and Cytogenetics 192*, 56–59.

Hansen, M. F., Nellissery, M. J., & Bhatia, P. (1999). Common mechanisms of osteosarcoma and Paget's disease. *Journal of Bone and Mineral Research 14*(Suppl. 2), 39–44.

Harada, N., Watanabe, Y., Yoshimura, Y., Sakumoto, H., Makishima, F., Tsuchiya, M., ... Aoki, Y. (2011). Identification of a checkpoint modulator with synthetic lethality to p53 mutants. *Anti-Cancer Drugs 22*, 986–994.

Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018). Current and future therapeutic approaches for osteosarcoma. *Expert Review of Anticancer Therapy 18*, 39–50.

Haupt, S., Hernandez, O. M., Vijayakumaran, R., Keam, S., & Haupt, Y. (2019). *The Long and the Short of it: the MDM4 Tail so far.* (J Mol Cell Biol).

He, Y., de Castro, L. F., Shin, M. H., Dubois, W., Yang, H. H., Jiang, S., ... Huang, J. (2015). p53 loss increases the osteogenic differentiation of bone marrow stromal cells. *Stem Cells 33*, 1304–1319.

Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017). The role of p53 in cancer drug resistance and targeted chemotherapy. *Oncotarget 8*, 8921–8946.

Ho, L., Stojanovski, A., Whetstone, H., Wei, Q. X., Mau, E., Wunder, J. S., & Alman, B. (2009). Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. *Cancer Cell 16*, 126–136.

Hu, F., Guo, X. L., Zhang, S. S., Zhao, Q. D., Li, R., Xu, Q., & Wei, L. X. (2017). Suppression of p53 potentiates chemosensitivity in nutrient-deprived cholangiocarcinoma cells via inhibition of autophagy. *Oncology Letters 14*, 1959–1966.

Huang, H. Y., Illei, P. B., Zhao, Z., Mazumdar, M., Huvos, A. G., Healey, J. H., ... Ladanyi, M. (2005). Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. *Journal of Clinical Oncology 23*, 548–558.

Huang, S. C., Zhang, L., Sung, Y. S., Chen, C. L., Kao, Y. C., Agaram, N. P., ... Antonescu, C. R. (2016). Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. *The American Journal of Surgical Pathology 40*, 645–655.

Hung, J., & Anderson, R. (1997). p53: functions, mutations and sarcomas. *Acta Orthopaedica Scandinavica. Supplementum 273*, 68–73.

Ignatius, M. S., Hayes, M. N., Moore, F. E., Tang, Q., Garcia, S. P., Blackburn, P. R., ... Langenau, D. M. (2018). tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. *eLife 7* (e37202).

In, G. K., Hu, J. S., & Tseng, W. W. (2017). Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. *Therapeutic advances in medical oncology 9*, 533–550.

Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., ... Lisztwan, J. (2011). Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. *Clinical Cancer Research 17*, 416–426.

Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2016). Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. *Oncotarget 7*, 5401–5415.

Jamil, N., Howie, S., & Salter, D. M. (2010). Therapeutic molecular targets in human chondrosarcoma. *International Journal of Experimental Pathology 91*, 387–393.

Jang, K. S., Min, K. W., Jang, S. H., Paik, S. S., Tae, K., Jang, S. J., & Park, M. H. (2007). Primary synovial sarcoma of the thyroid gland. *Journal of Korean Medical Science 22*(Suppl), S154–S158.

Jiang, H., Reinhardt, H. C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., ... Hemann, M. T. (2009). The combined status of ATM and p53 link tumor development with therapeutic response. *Genes & Development 23*, 1895–1909.

Kadoch, C., & Crabtree, G. R. (2015). Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Science Advances 1*, e1500447.

Kanojia, D., Nagata, Y., Garg, M., Lee, D. H., Sato, A., Yoshida, K., ... Koeffler, H. P. (2015). Genomic landscape of liposarcoma. *Oncotarget 6*, 42429–42444.

Karan, G., Wang, H., Chakrabarti, A., Karan, S., Liu, Z., Xia, Z., ... Wald, D. N. (2016). Identification of a small molecule that overcomes HdmX-mediated suppression of p53. *Molecular Cancer Therapeutics 15*, 574–582.

Kawai, A., Noguchi, M., Beppu, Y., Yokoyama, R., Mukai, K., Hirohashi, S., ... Fukuma, H. (1994). Nuclear immunoreaction of p53 protein in soft tissue sarcomas a possible prognostic factor. *Cancer 73*, 2499–2505.

Kim, M. J., Cho, K. J., Ayala, A. G., & Ro, J. Y. (2011). Chondrosarcoma: with updates on molecular genetics. *Sarcoma 2011*, 405437.

Kim, M. P., & Lozano, G. (2018). Mutant p53 partners in crime. *Cell Death and Differentiation 25*, 161–168.

Kollár, A., & Benson, C. (2014). Current management options for liposarcoma and challenges for the future. *Expert Review of Anticancer Therapy 14*, 297–306.

Komuro, H., Hayashi, Y., Kawamura, M., Hayashi, K., Kaneko, Y., Kamoshita, S., Hanada, R., Yamamoto, K., Hongo, T., Yamada, M., et al. (1993). Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. *Cancer Research 53*, 5284–5288.

Konomoto, T., Fukuda, T., Hayashi, K., Kumazawa, J., & Tsuneyoshi, M. (1998). Leiomyosarcoma in soft tissue: examination of p53 status and cell proliferating factors in different locations. *Human Pathology 29*, 74–81.

Kovar, H., Auinger, A., Jug, G., Aryee, D., Zoubek, A., Salzer-Kuntschik, M., & Gadner, H. (1993). Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. *Oncogene 8*, 2683–2690.

Kridis, W. B., Toumi, N., Chaari, H., Khanfir, A., Ayadi, K., Keskes, H., ... Frikha, M. (2017). A review of Ewing sarcoma treatment: is it still a subject of debate? *Reviews on Recent Clinical Trials 12*, 19–23.

Krieg, A. H., Hefti, F., Speth, B. M., Jundt, G., Guillou, L., Exner, U. G., ... Siebenrock, K. A. (2011). Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. *Annals of Oncology 22*, 458–467.

Ladanyi, M., Lewis, R., Jhanwar, S. C., Gerald, W., Huvos, A. G., & Healey, J. H. (1995). MDM2 and CDK4 gene amplification in Ewing's sarcoma. *The Journal of Pathology 175*, 211–217.

Landuzzi, L., Ianzano, M. L., Nicoletti, G., Palladini, A., Grosso, V., Ranieri, D., ... Lollini, P. L. (2014). Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. *Oncotarget 5*, 11924–11938.

Lane, D., & Levine, A. (2010). p53 Research: the past thirty years and the next thirty years. *Cold Spring Harbor Perspectives in Biology 2*, a000893.

Lane, D. P., Brown, C. J., Verma, C., & Cheok, C. F. (2011). New insights into p53 based therapy. *Discovery Medicine 12*, 107–117.

Lang, G. A., Iwakuma, T., Suh, Y. A., Liu, G., Rao, V. A., Parant, J. M., ... Lozano, G. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. *Cell 119*, 861–872.

Laroche-Clary, A., Chaire, V., Algeo, M. -P., Derieppe, M. -A., Loarer, F. L., & Italiano, A. (2017). Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. *Journal of Hematology & Oncology 10*, 123.

Le Guellec, S., Chibon, F., Ouali, M., Perot, G., Decouvelaere, A. V., Robin, Y. M., ... Neuville, A. (2014). Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? *The American Journal of Surgical Pathology 38*, 293–304.

de Leeuw, B., Balemans, M., Weghuis, D. O., & van Kessel, A. G. (1995). Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X; 18)(p11.2;q11.2)-positive synoviaol sarcomas. *Human Molecular Genetics 4*, 1097–1099.

Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F., Repapi, E., ... Jochemsen, A. G. (2012). Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Research 72, 4074–4084.

Lenos, K., & Jochemsen, A. G. (2011). Functions of MDMX in the modulation of the p53-response. Journal of Biomedicine & Biotechnology 2011, 876173.

Lerman, D. M., Monument, M. J., McIlvaine, E., Liu, X. Q., Huang, D., Monovich, L., ... Children's Oncology Group Ewing Sarcoma Biology, C (2015). Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the children's oncology group. Pediatric Blood & Cancer 62, 759–765.

Lessnick, S. L., Dacwag, C. S., & Golub, T. R. (2002). The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1, 393–401.

Leuschner, I., Langhans, I., Schmitz, R., Harms, D., Mattke, A., & Treuner, J. (2003). p53 and mdm-2 expression in rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the kiel pediatric tumor registry and the German cooperative soft tissue sarcoma study. Pediatric and Developmental Pathology 6, 128–136.

Lewis, J. J., Antonescu, C. R., Leung, D. H. Y., Blumberg, J. H., Healey, J. H., Woodruff, J. M., & Brennan, M. F. (2000). Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. Journal of Clinical Oncology 18, 2087–2094.

Li, Q., Zhang, Y., El-Naggar, A. K., Xiong, S., Yang, P., Jackson, J. G., ... Lozano, G. (2014). Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Molecular Cancer Research 12, 901–911.

Li, Y., Li, X., Fan, G., Fukushi, J., Matsumoto, Y., Iwamoto, Y., & Zhu, Y. (2012). Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Letters 320, 14–22.

Li, Y., Tanaka, K., Fan, X., Nakatani, F., Li, X., Nakamura, T., ... Iwamoto, Y. (2010). Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Letters 294, 57–65.

Lin, P. P., Wang, Y., & Lozano, G. (2011). Mesenchymal stem cells and the origin of Ewing's sarcoma. Sarcoma 2011.

Lu, S., Cai, C., Yan, G., Zhou, Z., Wan, Y., Chen, V., ... Lu, X. (2016). Signal-oriented pathway analyses reveal a signaling complex as a synthetic lethal target for p53 mutations. Cancer Research 76, 6785–6794.

Lye, K. L., Nordin, N., Vidyadaran, S., & Thilakavathy, K. (2016). Mesenchymal stem cells: from stem cells to sarcomas. Cell Biology International 40, 610–618.

Macchia, G., Severgnini, M., Purgato, S., Tolomeo, D., Casciaro, H., Cifola, I., ... Carella, M. (2018). The hidden genomic and transcriptomic plasticity of giant marker chromosomes in cancer. Genetics 208, 951–961.

Mäkinen, N., Aavikko, M., Heikkinen, T., Taipale, M., Taipale, J., Koivisto-Korander, R., ... Vahteristo, P. (2016). Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12. PLoS Genetics 12, e1005850.

Mäkinen, N., Kämpjärvi, K., Frizzell, N., Bützow, R., & Vahteristo, P. (2017). Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Molecular Cancer 16, 101.

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238.

Mandahl, N., Magnusson, L., Nilsson, J., Viklund, B., Arbajian, E., von Steyern, F. V., ... Mertens, F. (2017). Scattered genomic amplification in dedifferentiated liposarcoma. Molecular Cytogenetics 10, 25.

Mankin, H. J., Casas-Ganem, J., Kim, J. -I., Gebhardt, M. C., Hornicek, F. J., & Zeegen, E. N. (2004). Leiomyosarcoma of somatic soft tissues. Clinical Orthopaedics and Related Research 421, 225–231.

Mantovani, F., Collavin, L., & Del Sal, G. (2019). Mutant p53 as a guardian of the cancer cell. Cell Death and Differentiation 26, 199–212.

Martin, J. W., Squire, J. A., & Zielenska, M. (2012). The genetics of osteosarcoma. Sarcoma 2012, 627254.

Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987). Rearrangement of the p53 gene in human osteogenic sarcomas. Proceedings of the National Academy of Sciences of the United States of America 84, 7716–7719.

Matushansky, I., Charytonowicz, E., Mills, J., Siddiqi, S., Hricik, T., & Cordon-Cardo, C. (2009). MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Review of Anticancer Therapy 9, 1135–1144.

Mazzoleni, S., Bisogno, G., Garaventa, A., Cecchetto, G., Ferrari, A., Sotti, G., ... Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma, C (2005). Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer 104, 183–190.

McGovern, Y., Zhou, C. D., & Jones, R. L. (2017). Systemic therapy in metastatic or unresectable well-differentiated/dedifferentiated liposarcoma. Frontiers in Oncology 7 (292-292).

McManus, S., & Roux, S. (2012). The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. Journal of Molecular Signaling 7, 1.

Mehren, M. v., & Joensuu, H. (2018). Gastrointestinal stromal tumors. Journal of Clinical Oncology 36, 136–143.

Mendoza, S., Konishi, T., Dernell, W. S., Withrow, S. J., & Miller, C. W. (1998). Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Research 18, 4449–4453.

Meyer, M., & Seetharam, M. (2019). First-line therapy for metastatic soft tissue sarcoma. Current Treatment Options in Oncology 20, 6.

Miettinen, M., & Fetsch, J. F. (2006). Evaluation of biological potential of smooth muscle tumours. Histopathology 48, 97–105.

Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koeffler, H. P. (1996). Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Journal of Cancer Research and Clinical Oncology 122, 559–565.

Mirabello, L., Koster, R., Moriarity, B. S., Spector, L. G., Meltzer, P. S., Gary, J., ... Savage, S. A. (2015). A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discovery 5, 920–931.

Mirabello, L., Troisi, R. J., & Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115, 1531–1543.

Mirabello, L., Yeager, M., Mai, P. L., Gastier-Foster, J. M., Gorlick, R., Khanna, C., ... Savage, S. A. (2015). Germline TP53 variants and susceptibility to osteosarcoma. Journal of the National Cancer Institute 107.

Miura, Y., Keira, Y., Ogino, J., Nakanishi, K., Noguchi, H., Inoue, T., & Hasegawa, T. (2012). Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors. Pathology International 62, 16–27.

Miyajima, K., Tamiya, S., Oda, Y., Adachi, T., Konomoto, T., Toyoshiba, H., ... Tsuneyoshi, M. (2001). Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Letters 164, 177–188.

Momtahen, S., Curtin, J., & Mittal, K. (2016). Current chemotherapy and potential new targets in uterine leiomyosarcoma. Journal of clinical medicine research 8, 181–189.

Morandell, S., Reinhardt, H. C., Cannell, I. G., Kim, J. S., Ruf, D. M., Mitra, T., ... Yaffe, M. B. (2013). A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Reports 5, 868–877.

Morrow, J. J., & Khanna, C. (2015). Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. Critical Reviews in Oncogenesis 20, 173–197.

Mortus, J. R., Zhang, Y., & Hughes, D. P. (2014). Developmental pathways hijacked by osteosarcoma. Advances in Experimental Medicine and Biology 804, 93–118.

Muller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Saeter, G., & Myklebost, O. (2007). Potential for treatment of liposarcomas with the MDM2 antagonist nutlin-3A. International Journal of Cancer 121, 199–205.

Murali, R., Chandramohan, R., Moller, I., Scholz, S. L., Berger, M., Huberman, K., ... Griewank, K. G. (2015). Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 6, 36041–36052.

Murphey, M. D. (2007). World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Seminars in Musculoskeletal Radiology 11, 201–214.

Murphey, M. D., Gibson, M. S., Jennings, B. T., Crespo-Rodríguez, A. M., Fanburg-Smith, J., & Gajewski, D. A. (2006). Imaging of synovial sarcoma with radiologic-pathologic correlation. RadioGraphics 26, 1543–1565.

Naka, N., Takenaka, S., Araki, N., Miwa, T., Hashimoto, N., Yoshioka, K., ... Itoh, K. (2010). Synovial sarcoma is a stem cell malignancy. Stem Cells 28, 1119–1131.

Naka, N., Tomita, Y., Nakanishi, H., Araki, N., Hongyo, T., Ochi, T., & Aozasa, K. (1997). Mutations of p53 tumor-suppressor gene in angiosarcoma. International Journal of Cancer 71, 952–955.

Nakayama, T., Toguchida, J., Wadayama, B., Kanoe, H., Kotoura, Y., & Sasaki, M. S. (1995). MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. International Journal of Cancer 64, 342–346.

Nazeri, E., Gouran Savadkoohi, M., Majidzadeh, A. K., & Esmaeili, R. (2018). Chondrosarcoma: an overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. Critical Reviews in Oncology/Hematology 131, 102–109.

Neilsen, P. M., Pishas, K. I., Callen, D. F., & Thomas, D. M. (2011). Targeting the p53 pathway in Ewing sarcoma. Sarcoma 2011, 746939.

Ng, V. Y., Scharschmidt, T. J., Mayerson, J. L., & Fisher, J. L. (2013). Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Research 33, 2597–2604.

Nishitoh, H. (2011). CHOP is a multifunctional transcription factor in the ER stress response. The Journal of Biochemistry 151, 217–219.

Nyquist, K. B., Panagopoulos, I., Thorsen, J., Haugom, L., Gorunova, L., Bjerkehagen, B., ... Micci, F. (2012). Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS ONE 7, e49705.

Obrador-Hevia, A., Martinez-Font, E., Felipe-Abrio, I., Calabuig-Farinas, S., Serra-Sitjar, M., Lopez-Guerrero, J. A., ... Martin-Broto, J. (2015). RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. Cancer Investigation 33, 440–450.

Ognjanovic, S., Martel, G., Manivel, C., Olivier, M., Langer, E., & Hainaut, P. (2012). Low prevalence of TP53 mutations and MDM2 amplifications in pediatric rhabdomyosarcoma. Sarcoma 2012, 492086.

Ognjanovic, S., Olivier, M., Bergemann, T. L., & Hainaut, P. (2012). Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118, 1387–1396.

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., ... Jacks, T. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860.

Olsson, L., Paulsson, K., Bovee, J. V., & Nord, K. H. (2011). Clonal evolution through loss of chromosomes and subsequent polyploidization in chondrosarcoma. PLoS ONE 6, e24977.

O'neill, C., McBride, H., Connolly, L., & McCluggage, W. (2007). Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50, 851–858.

van Oosterwijk, J. G., van Ruler, M. A., Briaire-de Bruijn, I. H., Herpers, B., Gelderblom, H., van de Water, B., & Bovee, J. V. (2013). Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. *British Journal of Cancer 109*, 1214–1222.

Origanti, S., Cai, S. R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013). Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. *Oncogene 32*, 577–588.

Oshiro, Y., Chaturvedi, V., Hayden, D., Nazeer, T., Johnson, M., Johnston, D. A., ... Czerniak, B. (1998). Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. *Cancer 83*, 2324–2334.

Ouslander, J. G., & Beck, J. C. (1982). Paget's disease of bone. *Journal of the American Geriatrics Society 30*, 410–414.

Overholtzer, M., Rao, P. H., Favis, R., Lu, X. Y., Elowitz, M. B., Barany, F., ... Levine, A. J. (2003). The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. *Proceedings of the National Academy of Sciences of the United States of America 100*, 11547–11552.

Ozaki, T. (2015). Diagnosis and treatment of Ewing sarcoma of the bone: a review article. *Journal of Orthopaedic Science 20*, 250–263.

Pakos, E. E., Kyzas, P. A., & Ioannidis, J. P. (2004). Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. *Clinical Cancer Research 10*, 6208–6214.

Panagopoulos, I., Mertens, F., Isaksson, M., Domanski, H. A., Brosjo, O., Heim, S., ... Mandahl, N. (2002). Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. *Genes, Chromosomes & Cancer 35*, 340–352.

Pani, L., Horal, M., & Loeken, M. R. (2002). Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis. *Genes & Development 16*, 676–680.

Pant, V., Larsson, C. A., Aryal, N., Xiong, S., You, M. J., Quintas-Cardama, A., & Lozano, G. (2017). Tumorigenesis promotes Mdm4-S overexpression. *Oncotarget 8*, 25837–25847.

Parrales, A., & Iwakuma, T. (2015). Targeting oncogenic mutant p53 for cancer therapy. *Frontiers in Oncology 5*, 288.

Parrales, A., Ranjan, A., Iyer, S. V., Padhye, S., Weir, S. J., Roy, A., & Iwakuma, T. (2016). DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. *Nature Cell Biology 18*, 1233–1243.

Pasello, M., Manara, M. C., & Scotlandi, K. (2018). CD99 at the crossroads of physiology and pathology. *Journal of Cell Communication Signaling 12*, 55–68.

Patil, N., Ahmed Kabeer Rasheed, S., Abba, M., Hendrik Leupold, J., Schwarzbach, M., & Allgayer, H. (2014). A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma. *International Journal of Cancer 134*, 2808–2819.

Patterson, H., Gill, S., Fisher, C., Law, M. G., Jayatilake, H., Fletcher, C. D., ... Cooper, C. S. (1994). Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. *British Journal of Cancer 69*, 1052–1058.

Pedeutour, F., Forus, A., Coindre, J. M., Berner, J. M., Nicolo, G., Michiels, J. F., ... Myklebost, O. (1999). Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. *Genes, Chromosomes and Cancer 24*, 30–41.

Peng, T., Zhang, P., Liu, J., Nguyen, T., Bolshakov, S., Belousov, R., ... Lev, D. (2011). An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. *Laboratory Investigation 91*, 392–403.

Pérez-Losada, J., Pintado, B., Gutiérrez-Adán, A., Flores, T., Bañares-González, B., Calabia del Campo, J., ... Sánchez-García, I. (2000). The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. *Oncogene 19*, 2413.

Perot, G., Chibon, F., Montero, A., Lagarde, P., de The, H., Terrier, P., ... Aurias, A. (2010). Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. *The American Journal of Pathology 177*, 2080–2090.

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., ... Janeway, K. A. (2014). Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. *Proceedings of the National Academy of Sciences of the United States of America 111*, E5564–E5573.

Philippe, G., Huang, Y. H., Cheneval, O., Lawrence, N., Zhang, Z., Fairlie, D. P., ... Henriques, S. T. (2016). Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions. *Biopolymers 106*, 853–863.

Pishas, K. I., Al-Ejeh, F., Zinonos, I., Kumar, R., Evdokiou, A., Brown, M. P., ... Neilsen, P. M. (2011). Nutlin-3a is a potential therapeutic for ewing sarcoma. *Clinical Cancer Research 17*, 494–504.

Polychronidou, G., Karavasilis, V., Pollack, S. M., Huang, P. H., Lee, A., & Jones, R. L. (2017). Novel therapeutic approaches in chondrosarcoma. *Future Oncology 13*, 637–648.

Pourebrahim, R., Zhang, Y., Liu, B., Gao, R., Xiong, S., Lin, P. P., ... Lozano, G. (2017). Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. *Genes & Development 31*, 1847–1857.

Radig, K., Schneider-Stock, R., Rose, I., Mittler, U., Oda, Y., & Roessner, A. (1998). p53 and ras mutations in Ewing's sarcoma. *Pathology, Research and Practice 194*, 157–162.

Ragazzini, P., Gamberi, G., Pazzaglia, L., Serra, M., Magagnoli, G., Ponticelli, F., ... Bertoni, F. (2004). Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. *Histology and Histopathology 19*, 401–412.

Ranjan, A., & Iwakuma, T. (2016). Non-canonical cell death induced by p53. *International Journal of Molecular Sciences 17*.

Ravegnini, G., Mariño-Enriquez, A., Slater, J., Eilers, G., Wang, Y., Zhu, M., ... Fletcher, J. A. (2012). MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. *Modern Pathology 26*, 743.

Ray-Coquard, I., Blay, J. -Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., ... Bui, B. N. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. *The Lancet Oncology 13*, 1133–1140.

Reddy, S. V. (2004). Etiology of Paget's disease and osteoclast abnormalities. *Journal of Cellular Biochemistry 93*, 688–696.

Ren, Y. -X., Finckenstein, F. G., Abdueva, D. A., Shahbazian, V., Chung, B., Weinberg, K. I., ... Anderson, M. J. (2008). Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. *Cancer Research 68*, 6587–6597.

Renzi, S., Anderson, N. D., Light, N., & Gupta, A. (2019). Ewing-like sarcoma: An emerging family of round cell sarcomas. *Journal of Cellular Physiology 234*, 7999–8007.

Ribi, S., Baumhoer, D., Lee, K., Edison Teo, A. S., Madan, B., Zhang, K., ... Hillmer, A. M. (2015). TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. *Oncotarget 6*, 7727–7740.

Riggi, N., Cironi, L., Provero, P., Suva, M. L., Stehle, J. C., Baumer, K., ... Stamenkovic, I. (2006). Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. *Cancer Research 66*, 7016–7023.

Rodriguez, R., Rubio, R., Gutierrez-Aranda, I., Melen, G. J., Elosua, C., García-Castro, J., & Menendez, P. (2011). FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. *Stem Cells 29*, 179–192.

Rubin, B. P., Nishijo, K., Chen, H. I., Yi, X., Schuetze, D. P., Pal, R., ... Keller, C. (2011). Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. *Cancer Cell 19*, 177–191.

Rubio, R., García-Castro, J., Gutiérrez-Aranda, I., Paramio, J., Santos, M., Catalina, P., ... Rodríguez, R. (2010). Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. *Cancer Research 70*, 4185–4194.

Ruiz-Mesa, C., Goldberg, J. M., Coronado Munoz, A. J., Dumont, S. N., & Trent, J. C. (2015). Rhabdomyosarcoma in adults: new perspectives on therapy. *Current Treatment Options in Oncology 16*, 27.

Sakamoto, A. (2014). The molecular pathogenesis of dedifferentiated chondrosarcoma. *Indian Journal of Orthopaedics 48*, 262–265.

Samuel, A. M., Costa, J., & Lindskog, D. M. (2014). Genetic alterations in chondrosarcomas - keys to targeted therapies? *Cellular Oncology (Dordrecht) 37*, 95–105.

Sand, L. G., Szuhai, K., & Hogendoorn, P. C. (2015). Sequencing overview of Ewing sarcoma: a journey across genomic, epigenomic and transcriptomic landscapes. *International Journal of Molecular Sciences 16*, 16176–16215.

Sandberg, A. A. (2004). Genetics of chondrosarcoma and related tumors. *Current Opinion in Oncology 16*, 342–354.

Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H. Y., ... Sweet-Cordero, E. A. (2019). Genome-informed targeted therapy for osteosarcoma. *Cancer Discovery 9*, 46–63.

Scheidt, S., Jacobs, C., Koob, S., Welle, K., Walter, S., Jakob, J., ... Schmolders, J. (2019). Soft tissue sarcoma - a current review of the diagnostic and treatment strategies. *Zeitschrift für Orthopädie und Unfallchirurgie*. https://doi.org/10.1055/a-0820-6366.

Schhneider-stock, R., Onnasch, D., Haeckel, C., Mellin, W., S Franke, D., & Roessner, A. (1999). *Prognostic Significance of p53 Gene Mutations and p53 Protein Expression in Synovial SarcomasVol. 435.*.

Schneider-Stock, R., Ziegeler, A., Haeckel, C., Franke, D. -S., Rys, J., & Roessner, A. (1999). Prognostic relevance of p53 alterations and Mib-1 proliferation index in subgroups of primary liposarcomas. *Clinical Cancer Research 5*, 2830–2835.

Schrage, Y. M., Lam, S., Jochemsen, A. G., Cleton-Jansen, A. M., Taminiau, A. H., Hogendoorn, P. C., & Bovee, J. V. (2009). Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. *Journal of Cellular and Molecular Medicine 13*, 2843–2852.

Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., ... Baker, L. H. (2017). Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. *Cancer 123*, 90–97.

Seddon, B., Strauss, S. J., Whelan, J., Leahy, M., Woll, P. J., Cowie, F., ... Beare, S. (2017). Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. *The Lancet Oncology 18*, 1397–1410.

Seidinger, A. L., Mastellaro, M. J., Paschoal Fortes, F., Godoy Assumpcao, J., Aparecida Cardinalli, I., Aparecida Ganazza, M., ... Yunes, J. A. (2011). Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. *Cancer 117*, 2228–2235.

Seki, M., Nishimura, R., Yoshida, K., Shimamura, T., Shiraishi, Y., Sato, Y., ... Takita, J. (2015). Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. *Nature Communications 6*, 7557.

Seligson, N. D., Kautto, E. A., Passen, E. N., Stets, C., Toland, A. E., Millis, S. Z., ... Chen, J. L. (2018). BRCA1/2 functional loss defines a targetable subset in leiomyosarcoma. *Oncologist*. https://doi.org/10.1634/theoncologist.2018-0448.

Serrano, C., Romagosa, C., Hernandez-Losa, J., Simonetti, S., Valverde, C., Moline, T., ... Ramon, Y. C. S. (2016). RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. *Cancer 122*, 99–107.

Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M., ... Khan, J. (2014). Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discovery 4*, 216.

Simms, W. W., Ordonez, N. G., Johnston, D., Ayala, A. G., & Czerniak, B. (1995). p53 expression in dedifferentiated chondrosarcoma. *Cancer 76*, 223–227.

Skytting, B., Nilsson, G., Brodin, B., Xie, Y., Lundeberg, J., Uhlén, M., & Larsson, O. (1999). A novel fusion gene, SYT-SSX4, in synovial sarcoma. *JNCI: Journal of the National Cancer Institute 91*, 974–975.

Soares, J., Espadinha, M., Raimundo, L., Ramos, H., Gomes, A. S., Gomes, S., ... Saraiva, L. (2017). DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. *Molecular Oncology 11*, 612–627.

Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011). Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. *European Journal of Cancer 47*, 1432–1441.

Spiker, A. M., & Ramsey, M. L. (2018). *Cancer, Angiosarcoma.* Treasure Island (FL): In StatPearls.

Stacchiotti, S., & Van Tine, B. A. (2017). Synovial sarcoma: current concepts and future perspectives. *Journal of Clinical Oncology 36*, 180–187.

Stegmaier, S., Poremba, C., Schaefer, K. -L., Leuschner, I., Kazanowska, B., Békássy, A. N., ... Koscielniak, E. (2011). Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). *Pediatric Blood & Cancer 57*, 406–414.

Stenman, G., Andersson, H., Mandahl, N., Meis-Kindblom, J. M., & Kindblom, L. G. (1995). Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. *International Journal of Cancer 62*, 398–402.

Stewart, E., McEvoy, J., Wang, H., Chen, X., Honnell, V., Ocarz, M., ... Yang, Y. (2018). Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. *Cancer Cell 34*, 411–426 (e419).

Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., ... Stegmaier, K. (2018). Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. *The Journal of Experimental Medicine 215*, 2137–2155.

Stuart, E. T., Haffner, R., Oren, M., & Gruss, P. (1995). Loss of p53 function through PAX-mediated transcriptional repression. *The EMBO Journal 14*, 5638–5645.

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., ... Medina, J. C. (2014). Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. *Journal of Medicinal Chemistry 57*, 1454–1472.

Sun, X., Guo, W., Shen, J. K., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015). Rhabdomyosarcoma: advances in molecular and cellular biology. *Sarcoma 2015* (232010-232010).

Szymanska, J., Tarkkanen, M., Wiklund, T., Virolainen, M., Blomqvist, C., Asko-Seljavaara, S., ... Knuutila, S. (1996). Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. *Genes, Chromosomes and Cancer 15*, 89–94.

Tang, N., Song, W. X., Luo, J., Haydon, R. C., & He, T. C. (2008). Osteosarcoma development and stem cell differentiation. *Clinical Orthopaedics and Related Research 466*, 2114–2130.

Tarpey, P. S., Behjati, S., Cooke, S. L., Van Loo, P., Wedge, D. C., Pillay, N., ... Futreal, P. A. (2013). Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. *Nature Genetics 45*, 923–926.

Taubert, H., Meye, A., & Wurl, P. (1998). Soft tissue sarcomas and p53 mutations. *Molecular Medicine 4*, 365–372.

Taylor, A. C., Shu, L., Danks, M. K., Poquette, C. A., Shetty, S., Thayer, M. J., ... Harris, L. C. (2000). P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. *Medical and Pediatric Oncology 35*, 96–103.

Todorova, R. (2014). Ewing's sarcoma cancer stem cell targeted therapy. *Current Stem Cell Research & Therapy 9*, 46–62.

Toffoli, G., Biason, P., Russo, A., De Mattia, E., Cecchin, E., Hattinger, C. M., ... Serra, M. (2009). Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. *Clinical Cancer Research 15*, 3550–3556.

Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H., Herrera, G. E., Yamamuro, T., Kotoura, Y., Sasaki, M. S., Little, J. B., et al. (1992). Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. *Cancer Research 52*, 6194–6199.

Tongyang, L., Haiqiang, G., Meiyan, Z., Yingze, H., Shuting, J., Ying, L., & Jihong, Z. (2015). Synthetic lethal genes to mutant p53. *Yi Chuan 37*, 321–326.

Tornin, J., Hermida-Prado, F., Padda, R. S., Gonzalez, M. V., Alvarez-Fernandez, C., Rey, V., ... Fernandez-Nevado, L. (2018). FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway. *Neoplasia 20*, 44–56.

Totoki, Y., Yoshida, A., Hosoda, F., Nakamura, H., Hama, N., Ogura, K., ... Shibata, T. (2014). Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. *Genome Research 24*, 1411–1420.

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Higgins, B., Xia, M., ... Vassilev, L. T. (2013). MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. *Cancer Research 73*, 2587–2597.

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., ... Vassilev, L. T. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. *Proceedings of the National Academy of Sciences of the United States of America 103*, 1888–1893.

Tsuchiya, T., Sekine, K., Hinohara, S., Namiki, T., Nobori, T., & Kaneko, Y. (2000). Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. *Cancer Genetics and Cytogenetics 120*, 91–98.

Ueda, T., Healey, J. H., Huvos, A. G., & Ladanyi, M. (1997). Amplification of the MYC gene in osteosarcoma secondary to paget's disease of bone. *Sarcoma 1*, 131–134.

Uesato, S., Matsuura, Y., Matsue, S., Sumiyoshi, T., Hirata, Y., Takemoto, S., ... Enari, M. (2016). Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities. *Bioorganic & Medicinal Chemistry 24*, 1919–1926.

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., ... Liu, E. A. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science 303*, 844–848.

Veeraraghavan, J., Natarajan, M., Herman, T. S., & Aravindan, N. (2010). Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. *Anticancer Research 30*, 4007–4015.

Velletri, T., Xie, N., Wang, Y., Huang, Y., Yang, Q., Chen, X., ... Shi, Y. (2016). P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development. *Cell Death & Disease 7*, e2015.

Ventura, S., Aryee, D. N., Felicetti, F., De Feo, A., Mancarella, C., Manara, M. C., ... Scotlandi, K. (2016). CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-notch-mediated control of NF-kappaB signaling. *Oncogene 35*, 3944–3954.

Vlenterie, M., Hillebrandt-Roeffen, M. H. S., Flucke, U. E., Groenen, P. J. T. A., Tops, B. B. J., Kamping, E. J., ... Versleijen-Jonkers, Y. M. H. (2015). Next generation sequencing in synovial sarcoma reveals novel gene mutations. *Oncotarget 6*, 34680–34690.

Vos, M., Koseła-Paterczyk, H., Rutkowski, P., van Leenders, G. J. L. H., Normantowicz, M., Lecyk, A., ... Grünhagen, D. J. (2018). Differences in recurrence and survival of extremity liposarcoma subtypes. *European Journal of Surgical Oncology 44*, 1391–1397.

Wadayama, B., Toguchida, J., Yamaguchi, T., Sasaki, M. S., & Yamamuro, T. (1993). p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. *British Journal of Cancer 68*, 1134–1139.

Wade, M., Li, Y. -C., & Wahl, G. M. (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nature Reviews Cancer 13*, 83.

Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., ... Hong, D. S. (2017). Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. *Journal of Clinical Oncology 35*, 1304–1311.

Walkley, C. R., Qudsi, R., Sankaran, V. G., Perry, J. A., Gostissa, M., Roth, S. I., ... Orkin, S. H. (2008). Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. *Genes & Development 22*, 1662–1676.

Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012). MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. *Acta Biochimica et Biophysica Sinica Shanghai 44*, 685–691.

Wang, L., Motoi, T., Khanin, R., Olshen, A., Mertens, F., Bridge, J., ... Ladanyi, M. (2012). Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. *Genes, Chromosomes & Cancer 51*, 127–139.

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barriere, C., ... Debussche, L. (2014). SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. *Cancer Research 74*, 5855–5865.

Wang, X., & Simon, R. (2013). Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics 6*, 30.

Wang, X. H., Zhang, S. F., Bao, J. Y., & Liu, F. Y. (2017). Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. *Tumour Biology 39*, 1010428317701638.

Wang, Z., & Sun, Y. (2010). Targeting p53 for novel anticancer therapy. *Translational Oncology 3*, 1–12.

Wassman, C. D., Baronio, R., Demir, O., Wallentine, B. D., Chen, C. K., Hall, L. V., ... Amaro, R. E. (2013). Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. *Nature Communications 4*, 1407.

Weidle, U. H., Maisel, D., & Eick, D. (2011). Synthetic lethality-based targets for discovery of new cancer therapeutics. *Cancer Genomics Proteomics 8*, 159–171.

Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003). CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. *Oncogene 22*, 8233–8245.

Wunder, J. S., Gokgoz, N., Parkes, R., Bull, S. B., Eskandarian, S., Davis, A. M., ... Andrulis, I. L. (2005). TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. *Journal of Clinical Oncology 23*, 1483–1490.

Xia, S. J., Pressey, J. G., & Barr, F. G. (2002). Molecular pathogenesis of rhabdomyosarcoma. *Cancer Biology & Therapy 1*, 97–104.

Xia, Y., Du, Z., Wang, X., & Li, X. (2018). Treatment of uterine sarcoma with rAd-p53 (gendicine) followed by chemotherapy: clinical study of TP53 gene therapy. *Human Gene Therapy 29*, 242–250.

Xie, Z., Babiceanu, M., Kumar, S., Jia, Y., Qin, F., Barr, F. G., & Li, H. (2016). Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. *Proceedings of the National Academy of Sciences of the United States of America 113*, 13126–13131.

Xiong, S., Tu, H., Kollareddy, M., Pant, V., Li, Q., Zhang, Y., ... Lozano, G. (2014). Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. *Proceedings of the National Academy of Sciences of the United States of America 111*, 11145–11150.

Xu, J., Timares, L., Heilpern, C., Weng, Z., Li, C., Xu, H., ... Athar, M. (2010). Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. *Cancer Research 70*, 6566–6576.

Yang, J., Du, X., Chen, K., Ylipää, A., Lazar, A. J. F., Trent, J., ... Zhang, W. (2009). Genetic aberrations in soft tissue leiomyosarcoma. *Cancer Letters 275*, 1–8.

Yao, D., Cai, G. H., Chen, J., Ling, R., Wu, S. X., & Li, Y. P. (2014). Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. *International Journal of Clinical and Experimental Pathology 7*, 6725–6733.

Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., ... Yang, D. J. (2018). A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. *Journal of Experimental & Clinical Cancer Research 37*, 97.

Yochum, T. R. (1984). Paget's sarcoma of bone. *Radiology 24*, 428–433.

Young, R. J., Brown, N. J., Reed, M. W., Hughes, D., & Woll, P. J. (2010). Angiosarcoma. *The Lancet Oncology 11*, 983–991.

Yu, D., Kahen, E., Cubitt, C. L., McGuire, J., Kreahling, J., Lee, J., ... Reed, D. R. (2015). Identification of synergistic, clinically achievable, combination therapies for osteosarcoma. *Scientific Reports 5*, 16991.

Zache, N., Lambert, J. M., Rokaeus, N., Shen, J., Hainaut, P., Bergman, J., ... Bykov, V. J. (2008). Mutant p53 targeting by the low molecular weight compound STIMA-1. *Molecular Oncology 2*, 70–80.

Zhang, N., Liu, H., Yue, G., Zhang, Y., You, J., & Wang, H. (2016). Molecular heterogeneity of Ewing sarcoma as detected by ion torrent sequencing. *PLoS ONE 11*, e0153546.

Zhang, W. -W., Li, L., Li, D., Liu, J., Li, X., Li, W., ... Lin, H. (2018). The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. *Human Gene Therapy 29*, 160–179.

Zhang, Y., Hu, Q., Li, G., Li, L., Liang, S., Zhang, Y., ... Xiong, S. (2018). ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway. *Cellular Physiology and Biochemistry 48*, 1099–1111.

Zhang, Y., Yang, J., Zhao, N., Wang, C., Kamar, S., Zhou, Y., ... Yang, Z. (2018). Progress in the chemotherapeutic treatment of osteosarcoma. *Oncology Letters 16*, 6228–6237.

Zhou, X., Hao, Q., & Lu, H. (2018). *Mutant p53 in Cancer Therapy - The Barrier or the Path.* J Mol Cell Biol.

Zietz, C., Rossle, M., Haas, C., Sendelhofert, A., Hirschmann, A., Sturzl, M., & Lohrs, U. (1998). MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. *The American Journal of Pathology 153*, 1425–1433.

Zuffa, E., Mancini, M., Brusa, G., Pagnotta, E., Hattinger, C. M., Serra, M., ... Santucci, M. A. (2008). P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. *International Journal of Radiation Biology 84*, 591–601.